🏷

Classifications

Harrison's Part

🔗

Mappings

MONDO

MONDO:0008758 mitochondrial DNA depletion syndrome 4a

MONDO:0008758 is the entity for Alpers-Huttenlocher syndrome, carried under the molecular label mitochondrial DNA depletion syndrome 4a and defined as the cerebrohepatopathy characterized by the triad of progressive developmental regression, intractable seizures, and hepatic failure. The clinical eponym is used as the entry name and preferred_term because that is what the literature and the clinic use.

👪

Inheritance

1

Autosomal recessive HP:0000007

Biallelic pathogenic variants in POLG. Both alleles must be affected; heterozygous carriers do not develop the syndrome, although heterozygous POLG variation is separately and importantly associated with susceptibility to valproate-induced liver injury in people who do not have the disease at all.

Autosomal recessive inheritance

Show evidence (3 references)

PMID:20138553 SUPPORT Human Clinical

"Molecular studies revealed homozygous p.R597W or p.A467T mutations in two patients. The other two patients showed compound heterozygous mutations, p.A467T/p.Q68X and p.L83P/p.G888S."

Four patients, two homozygous and two compound heterozygous, which is the biallelic pattern of autosomal recessive inheritance.

PMID:20301791 SUPPORT Other

"If both parents are known to be heterozygous for a POLG pathogenic variant, each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants and being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial..."

The GeneReviews recurrence-risk statement, which is the practical content of the inheritance mode for a family. The 25/50/25 split is what autosomal recessive means at the bedside, and it is stated here rather than left to be inferred from the mode alone.

PMID:20301791 SUPPORT Other

"Heterozygous sibs of a proband with an autosomal recessive POLG-related disorder are typically asymptomatic."

Confirms that carriers do not have the syndrome, which is the claim this block makes and which has to be stated carefully here, because heterozygous POLG variation is separately associated with valproate hepatotoxicity risk. Asymptomatic for the disease is not the same as free of drug risk.

?

Discussions and Knowledge Gaps

3

If valproate hepatotoxicity in POLG disease is not mediated through mitochondrial DNA depletion, mutation, or impaired fatty acid metabolism, what does mediate it, and is impaired liver regeneration sufficient to explain a fatal outcome?

CONTROVERSY UNDER DISCUSSION ahs_valproate_toxicity_mechanism

Attached to

pathophysiology#Valproate-Precipitated Fulminant Hepatic Failure

The intuitive account of this toxicity is almost irresistible: the disease is a mitochondrial DNA depletion syndrome, valproate has known mitochondrial effects, so valproate must be making the depletion worse. That account was tested and it failed. Toxicity was found not to be mediated through mitochondrial DNA depletion, not through mutation, and not through a defect of fatty acid metabolism, which removes all three of the obvious routes at once. What was found instead was that valproate inhibits human cellular proliferation at therapeutic doses and causes non-apoptotic cell death at high ones, and the authors read this as implicating impaired liver regeneration. That is a coherent story but it leaves real gaps. It does not explain the tissue specificity, since valproate reaches many proliferating tissues and the liver is the one that fails. It does not obviously explain the two-to-three-month latency, which is long for a direct antiproliferative effect and might instead reflect the time taken to exhaust a regenerative reserve. And it sits awkwardly with the strength of the genetic association, an odds ratio above twenty for heterozygous variation, since a mechanism that is independent of the mitochondrial genome ought to explain why POLG genotype matters so much. Resolving this is not merely mechanistic housekeeping: if the mediator were identified, it might be possible to make valproate safe rather than merely to avoid it.

Proposed experiments

Regenerative challenge in a POLG-variant hepatocyte model

ahs_regeneration_challenge_model

Partial-hepatectomy-style regenerative challenge, or its in-vitro equivalent using proliferation after controlled injury, in hepatocyte models carrying the recurrent POLG variants against isogenic controls, with and without valproate at therapeutic concentrations, measuring regenerative capacity rather than baseline viability.

Decision criterion

A selective failure of regeneration in POLG-variant cells under valproate, with preserved baseline viability, would confirm impaired regeneration as the mediator. Equivalent regenerative failure regardless of POLG genotype would indicate the genotype acts through something else.

Comparison of valproate antiproliferative effect across tissue lineages

ahs_tissue_specificity_comparison

Parallel measurement of valproate's antiproliferative effect in hepatocyte, intestinal epithelial and haematopoietic progenitor models carrying the same POLG variants, testing whether the liver is uniquely sensitive or merely uniquely exposed.

Decision criterion

Selective hepatocyte sensitivity would support a liver-specific mechanism and direct the search there. Comparable sensitivity across lineages would indicate the clinical liver specificity comes from exposure, first-pass concentration, or regenerative demand rather than from cellular susceptibility.

Testing whether latency reflects exhaustion of regenerative reserve

ahs_latency_reserve_modelling

Serial measurement of hepatic regenerative and functional markers from the start of valproate exposure in children with known POLG variants who require the drug's continuation for compelling reasons, or in a suitable animal model, to determine whether the two-to-three-month interval corresponds to a progressive decline or to an abrupt threshold event.

Decision criterion

A progressive measurable decline preceding failure would support reserve exhaustion and would identify a monitoring window. An abrupt transition without antecedent change would argue against the reserve model and against the feasibility of monitoring.

Show evidence (4 references)

PMID:21038416 REFUTE In Vitro

"Therapeutic doses of VPA inhibited human cellular proliferation and high doses caused nonapoptotic cell death, which was not mediated through mitochondrial DNA depletion, mutation, or a defect of fatty acid metabolism."

The negative result that creates the controversy, excluding all three intuitive mechanisms in a single experiment.

PMID:21038416 SUPPORT In Vitro

"These findings implicate impaired liver regeneration in VPA toxicity"

The positive hypothesis put in place of the refuted ones, which the proposed experiments are designed to test directly.

PMID:21038416 SUPPORT Human Clinical

"Heterozygous genetic variation in POLG was strongly associated with VPA-induced liver toxicity"

The strength of the genotype effect, reported in the same sentence as an odds ratio of 23.6, is what a non-mitochondrial mechanism has to account for, and is the tension this discussion identifies.

+ 1 more reference

Which children with intractable seizures should have POLG sequenced before valproate is started, and can a test that takes days be made to govern a decision that is often made in hours?

OPEN QUESTION OPEN ahs_polg_testing_threshold

Attached to

pathophysiology#Valproate-Precipitated Fulminant Hepatic Failure

The proposal in the literature is broad: consider POLG testing in any child or adolescent who presents with or develops intractable seizures, with or without status epilepticus or epilepsia partialis continua. That is described as an emerging standard of care rather than an established one, and the gap between those two phrases is where the real question lives. Arguments for the broad threshold are strong. The consequence of missing the diagnosis is a preventable death, POLG variants occur in every ancestry group so no population can be excluded, and the risk extends beyond the syndrome itself because heterozygous variation alone carries a substantially elevated risk. Arguments against a universal rule are practical rather than principled. Intractable seizures are common and this disease is rare, so a broad rule tests very many children to find few; sequencing turnaround is usually days while the decision to start valproate is often made the same day; and variants of uncertain significance in a large gene will generate results that are themselves hard to act on. What is genuinely unresolved is not whether testing helps but what the operating policy should be, and no study has compared candidate thresholds against outcomes.

Proposed experiments

Diagnostic yield and outcome by testing threshold

ahs_testing_yield_by_threshold

Retrospective and then prospective evaluation across paediatric epilepsy centres of several candidate testing thresholds, from the broadest (all intractable seizures) to narrower ones (epilepsia partialis continua, occipital electrographic predominance, regression, or any combination), measuring diagnostic yield, number needed to test, and cases of valproate hepatotoxicity averted.

Decision criterion

A threshold that captures nearly all cases at an acceptable number needed to test would justify a specific policy recommendation. If yield falls steeply as soon as the threshold is narrowed at all, that argues for the broad rule despite its cost.

Rapid targeted genotyping of recurrent variants as a pre-prescription test

ahs_rapid_targeted_genotyping

Development and evaluation of a same-day targeted assay for the recurrent POLG variants, including p.A467T, p.R597W and p.Q1236H, deployed as a pre-prescription check rather than as a diagnostic test, with sensitivity measured against full sequencing.

Decision criterion

If a rapid targeted panel captures a large majority of clinically relevant genotypes, it can govern the prescribing decision in real time while full sequencing proceeds. Low sensitivity would mean the panel gives false reassurance and should not be used this way.

Outcome of a policy of avoiding valproate first-line in intractable childhood seizures

ahs_alternative_first_line_policy

Comparison of centres that avoid valproate as a first-line agent in undiagnosed intractable childhood seizures against those that do not, measuring both hepatotoxicity events and any cost in seizure control from the deferred use of an effective drug.

Decision criterion

If avoidance prevents hepatotoxicity at little cost in seizure control, policy can sidestep the testing-turnaround problem entirely. A meaningful loss of seizure control would mean testing, not avoidance, is the right instrument.

Show evidence (3 references)

PMID:20138553 SUPPORT Human Clinical

"Our data support an emerging proposal that POLG gene testing should be considered in any child or adolescent who presents or develops intractable seizures with or without status epilepticus or epilepsia partialis"

The broad threshold under discussion, stated by its proponents as an emerging proposal rather than as settled practice.

PMID:20138553 SUPPORT Human Clinical

"POLG mutations have been observed in every ethnic group studied to date"

Removes ancestry as a legitimate basis for narrowing the testing threshold.

PMID:21038416 SUPPORT Human Clinical

"prospective genetic testing of POLG will identify individuals at high risk of this potentially fatal consequence of treatment"

Supports prospective testing and, by covering heterozygotes without the syndrome, widens the population for whom testing has value beyond suspected Alpers-Huttenlocher syndrome.

Post-mortem work shows the respiratory chain deficiency falls preferentially on inhibitory interneurons of the occipital cortex, but why those cells and why that lobe, when every neuron carries the same POLG genotype? And does occipital cortex have a general vulnerability that mechanistically unrelated epilepsies all expose?

KNOWLEDGE GAP OPEN ahs_occipital_predominance

Attached to

pathophysiology#Selective Interneuron and Pyramidal Neuron Loss in Occipital Cortex

This gap has moved rather than closed, and it is worth being precise about what part of it the evidence now answers. A systemic defect in replicating the mitochondrial genome should not have a lobe preference, yet the epileptiform activity of this disease has one. Quantitative neuropathology supplies the missing middle term: the deficiency is not uniform across cortex but concentrated in inhibitory interneurons and pyramidal neurons of occipital cortex and in Purkinje cells, and those populations are depleted. So the chain from a genome-maintenance defect to occipital seizures now has a cellular link in it, and the entry models that link rather than leaving a hole. What remains open is the selectivity itself, at two levels. Why interneurons: the usual explanation is that fast-spiking inhibitory cells carry the highest sustained metabolic load in cortex and so fail first under a shared energetic constraint, which is plausible and, in these sources, untested. Why occipital: nothing explains why the same cell class fails there rather than in frontal or temporal cortex, and the study did not compare regions within a brain in a way that would settle it. The authors themselves state their causal reading as a belief rather than a demonstration. There is also a caution against over-reading the regional claim. The electrographic and imaging findings vary between patients and between stages, which is not what a fixed metabolic gradient would produce. Finally, the company this observation keeps still matters. This knowledge base contains two other occipital-onset epilepsies, childhood occipital visual epilepsy and photosensitive occipital lobe epilepsy, which share no etiology with this disease or with each other beyond the location. The interneuron finding makes that convergence more interesting rather than less: if occipital inhibitory circuitry has a general fragility, a bioenergetic disease and two idiopathic epilepsies could be exposing the same weak point by different routes. No single-disease study can test that.

Proposed experiments

Testing whether interneuron selectivity follows metabolic load

ahs_interneuron_metabolic_load

Within the same post-mortem brains, comparison of respiratory chain subunit deficiency between fast-spiking parvalbumin-positive interneurons and lower-firing interneuron subtypes, against a measure of each population's baseline metabolic demand. This asks directly whether the vulnerable population is the one with the highest sustained energy requirement, which is the standard explanation and has not been tested here.

Decision criterion

Deficiency tracking firing rate and metabolic demand across interneuron subtypes would establish energetic load as the selectivity mechanism. Uniform deficiency across subtypes, or selectivity that does not follow demand, would mean something other than metabolic load picks the vulnerable cells.

Regional quantification of mitochondrial DNA depletion in post-mortem brain

ahs_regional_mtdna_quantification

Quantification of mitochondrial DNA copy number and respiratory chain subunit expression across cortical regions in post-mortem tissue from patients with POLG disease, testing directly whether occipital cortex is more depleted or more functionally compromised than frontal and temporal cortex in the same brain.

Decision criterion

Greater occipital depletion within the same brain would support a regional metabolic vulnerability. Uniform depletion across regions would mean the electrographic predominance arises from network properties rather than from where the molecular lesion bites hardest.

Occipital predominance across mitochondrial diseases

ahs_cross_mitochondrial_disease_eeg_survey

Systematic review of interictal electroencephalographic localization across mitochondrial diseases with differing molecular lesions, testing whether occipital predominance tracks mitochondrial dysfunction in general or is specific to POLG.

Decision criterion

A shared occipital predominance across mitochondrial diseases would support a general energetic vulnerability of occipital cortex. Specificity to POLG would point to something about this lesion in particular.

Cross-etiology comparison of occipital epileptogenicity

ahs_cross_etiology_occipital_comparison

Comparison of occipital cortical excitability measures, such as the visual evoked response amplitude and after-discharge parameters already used in photosensitive occipital lobe epilepsy, across patients with POLG disease, the self-limited occipital epilepsies of childhood, and controls, to test whether a shared occipital excitability trait exists independent of etiology.

Decision criterion

A shared excitability abnormality across etiologically unrelated occipital epilepsies would establish a general vulnerability worth modelling as such. Divergent physiology would mean the convergence on one lobe is coincidental and each disease reaches it by its own route.

Show evidence (4 references)

PMID:30021052 SUPPORT Human Clinical

"Quantitative immunofluorescence showed severe respiratory chain deficiencies involving mitochondrial respiratory chain subunits of complex I and, to a lesser extent, complex IV in inhibitory interneurons and pyramidal neurons in the occipital cortex and in Purkinje cells of the cerebellum...."

The evidence that moved this gap rather than closing it. It establishes the cellular selectivity and its occipital location, which is the part of the question that is now answered, and says nothing about why those cells or that lobe, which is the part that remains open.

PMID:30021052 SUPPORT Human Clinical

"Since our understanding of the mechanisms contributing the neurological features in Alpers' syndrome is rudimentary, we performed a detailed and quantitative neuropathological study on 13 patients with clinically and histologically-defined Alpers' syndrome with ages ranging from 2 months to 18 years."

The authors' own characterization of mechanistic understanding in this disease as rudimentary, which is the state this gap records, together with the cohort size that bounds how much the study can settle.

PMID:20138553 SUPPORT Human Clinical

"early predominance of epileptiform discharges over the occipital region is common in POLG-induced epilepsy"

The observation this gap is about, reported as common and useful enough to serve as a recognition feature.

+ 1 more reference

⚙

Pathophysiology

9

Biallelic Loss of DNA Polymerase Gamma Function

The proximal lesion. Both POLG alleles carry pathogenic variants, so the catalytic subunit of polymerase gamma is impaired in fidelity, processivity or abundance. Because polymerase gamma is the sole replicative polymerase of the mitochondrial genome, there is no backup enzyme, and the consequence of the lesion falls entirely on mitochondrial DNA rather than being buffered by the nuclear replication machinery.

POLG hgnc:9179

DNA-directed DNA polymerase activity GO:0003887 ↓ DECREASED

Downstream

Failure of Mitochondrial DNA Replication

Show evidence (2 references)

PMID:21038416 SUPPORT Human Clinical

"Rare mutations in POLG, which codes for the mitochondrial DNA polymerase γ (polγ), cause Alpers-Huttenlocher syndrome (AHS)."

Establishes the causal relationship between loss of this specific enzyme and the syndrome.

PMID:21038416 SUPPORT In Vitro

"This was principally due to the p.Q1236H substitution which compromised polγ function in yeast."

Functional demonstration in a model system that a POLG substitution compromises the enzyme, supporting loss of function as the mechanism rather than a purely statistical association.

Failure of Mitochondrial DNA Replication

Mitochondrial DNA is not a static archive; it turns over and must be continually re-replicated even in cells that never divide. With polymerase gamma impaired, replication cannot keep pace with that turnover, which is why a replication defect produces a quantitative loss of genome copies rather than only a mutational burden.

mitochondrial DNA replication GO:0006264 ↓ DECREASED

Downstream

Tissue Mitochondrial DNA Depletion

Show evidence (1 reference)

PMID:21038416 SUPPORT Human Clinical

"Rare mutations in POLG, which codes for the mitochondrial DNA polymerase γ (polγ), cause Alpers-Huttenlocher syndrome (AHS)."

Names the enzyme as the mitochondrial DNA polymerase, which is what makes replication of that genome the process this node describes.

Tissue Mitochondrial DNA Depletion

Loss of mitochondrial genome copy number in affected tissues, most prominently brain and liver. This is the feature that places the disease in the mitochondrial DNA depletion syndromes and gives the MONDO entity its molecular name. The tissue selectivity is not fully explained by energy demand alone, but brain and liver are where the clinical disease appears.

hepatocyte CL:0000182 neuron CL:0000540

liver UBERON:0002107

Downstream

Respiratory Chain Deficiency and Cellular Energy Failure

Show evidence (1 reference)

PMID:20301791 SUPPORT Human Clinical

"POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined before the molecular basis was known."

Supports that a single molecular lesion underlies phenotypes that were separately described clinically. Marked PARTIAL because it establishes the shared molecular basis without quantifying depletion in specific tissues.

Respiratory Chain Deficiency and Cellular Energy Failure

Because the mitochondrial genome encodes core subunits of the respiratory chain, losing genome copies means losing the capacity to build those complexes, and oxidative phosphorylation falls. The cells that decompensate first are the ones with the least metabolic slack, which is the general explanation for why a systemic replication defect presents as a brain and liver disease.

neuron CL:0000540 hepatocyte CL:0000182

Downstream

Selective Interneuron and Pyramidal Neuron Loss in Occipital Cortex

Hepatocellular Dysfunction and Failure

Progressive Developmental Regression

Show evidence (1 reference)

PMID:20301791 SUPPORT Human Clinical

"POLG-related disorders can therefore be considered an overlapping spectrum of disease presenting from early childhood to late adulthood."

Supports a shared underlying mechanism expressed across a range of severities and ages. Marked PARTIAL because the abstract does not itself measure respiratory chain function.

Selective Interneuron and Pyramidal Neuron Loss in Occipital Cortex

The energy failure does not fall evenly on the cortex, and quantitative post-mortem work says where it lands. In the largest series of Alpers brains examined this way, severe respiratory chain deficiency involving complex I, and to a lesser extent complex IV, was found in inhibitory interneurons and pyramidal neurons of the occipital cortex and in cerebellar Purkinje cells, with reduced densities of those same populations. That is the mechanistic content behind the syndrome's otherwise puzzling occipital emphasis, and it is why this node conforms to the module's excitation-inhibition node rather than only to a generic degeneration: losing inhibitory interneurons preferentially is an excitation-inhibition imbalance in the most literal sense, arrived at through bioenergetic failure instead of through a channel defect. The same finding accounts for the cerebellar signs, since Purkinje cells are the sole output of the cerebellar cortex. The classical description of the disease as a progressive sclerosing poliodystrophy refers to this grey-matter loss.

inhibitory interneuron CL:0000099 GABAergic neuron CL:0000617 Purkinje cell CL:0000121

mitochondrial ATP synthesis coupled electron transport GO:0042775 ↓ DECREASED

occipital lobe UBERON:0002021 cerebellar cortex UBERON:0002129

Downstream

Intractable Focal Epilepsy and Epilepsia Partialis Continua

Show evidence (5 references)

PMID:30021052 SUPPORT Human Clinical

"Quantitative immunofluorescence showed severe respiratory chain deficiencies involving mitochondrial respiratory chain subunits of complex I and, to a lesser extent, complex IV in inhibitory interneurons and pyramidal neurons in the occipital cortex and in Purkinje cells of the cerebellum...."

The quantitative post-mortem basis for every claim in this node: which complexes fail, which cell populations they fail in, that those populations include inhibitory interneurons, that the cortical site is occipital, and that the cells are actually lost rather than merely impaired.

PMID:30021052 SUPPORT Human Clinical

"We believe interneuron and Purkinje cell pathology underpins the clinical development of seizures and ataxia seen in Alpers' syndrome."

The authors' own causal reading, which is what licenses this node's downstream edge to the epilepsy and its conformance to the excitation-inhibition node of the module. Their framing is a belief rather than a demonstration, which the discussion below preserves.

PMID:30021052 SUPPORT Human Clinical

"This study also further highlights the extensive involvement of GABAergic neurons in mitochondrial disease."

Identifies the vulnerable interneurons as GABAergic, which is the specific inhibitory population whose loss makes this an excitation-inhibition imbalance rather than a nonspecific cell loss.

+ 2 more references

Intractable Focal Epilepsy and Epilepsia Partialis Continua

Focal seizures that do not respond to medication, frequently escalating to epilepsia partialis continua, a state of continuous focal motor seizure activity that can persist for days or longer. In the reported series most children who went on to valproate hepatotoxicity had developed epilepsia partialis continua, which is the clinical reason the drug was reached for in the first place and is therefore the hinge between the two arms of this pathograph.

Downstream

Valproate-Precipitated Fulminant Hepatic Failure

Show evidence (2 references)

PMID:20138553 SUPPORT Human Clinical

"All were given VPA due to intractable partial seizures. Three of the patients had developed epilepsia partialis continua."

Establishes both the intractable focal epilepsy and the frequency of epilepsia partialis continua, and shows that the seizures are what led to the drug exposure.

PMID:20138553 SUPPORT Human Clinical

"POLG gene testing should be considered in any child or adolescent who presents or develops intractable seizures with or without status epilepticus or epilepsia partialis"

The authors' proposed trigger for testing, which is stated in terms of this seizure phenotype.

Progressive Developmental Regression

Loss of previously acquired skills in a child who had been developing normally, which with the seizures and the liver failure completes the defining triad. Regression rather than delay is the key observation: these children had the skills and lost them, which points to a degenerative process rather than a developmental one.

Show evidence (1 reference)

PMID:20301791 SUPPORT Human Clinical

"The age of onset broadly correlates with the clinical phenotype."

Supports that the early-onset presentation this entry models is a distinct point on the POLG continuum. Marked PARTIAL because the abstract states the age-phenotype relationship rather than describing regression itself, which is taken from the MONDO definition of the triad.

Hepatocellular Dysfunction and Failure

Liver failure is the third element of the triad and is frequently what determines survival. It can develop as part of the natural history, without any drug exposure, which is what distinguishes the intrinsic hepatic arm of this pathograph from the valproate-precipitated one downstream of it.

hepatocyte CL:0000182

liver UBERON:0002107

Downstream

Valproate-Precipitated Fulminant Hepatic Failure

Show evidence (2 references)

PMID:21038416 SUPPORT Human Clinical

"AHS is a neurometabolic disorder associated with an increased risk of developing fatal VPA hepatotoxicity."

Names the syndrome as neurometabolic and establishes the hepatic vulnerability that both this node and the one downstream of it depend on.

PMID:20301791 SUPPORT Human Clinical

"Early-onset disease (prior to age 12 years): Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features. This group has the worst prognosis."

Names liver involvement among the most common features of the early-onset group, alongside the seizures, which is the co-occurrence this pathograph models.

Valproate-Precipitated Fulminant Hepatic Failure

The iatrogenic arm, and the reason this disease has to be recognized before it is treated. Sodium valproate is a reasonable choice for intractable focal seizures and is widely used; in a child with POLG disease it can precipitate liver failure at any stage of the illness, typically within two to three months of starting it, and it is often fatal. What the mechanism is not, is as informative as what it is: the toxicity was found not to be mediated through mitochondrial DNA depletion, through mutation, or through a defect in fatty acid metabolism, which rules out the intuitive explanation that valproate simply accelerates the underlying lesion. The finding instead implicates impaired liver regeneration, with valproate inhibiting cellular proliferation at therapeutic doses and causing non-apoptotic cell death at high ones.

hepatocyte CL:0000182

liver UBERON:0002107

Show evidence (4 references)

PMID:20138553 SUPPORT Human Clinical

"VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate liver failure"

The core clinical claim of this node, stated without qualification about disease stage, which is what makes the avoidance absolute rather than conditional.

PMID:20138553 SUPPORT Human Clinical

"The time from VPA exposure to liver failure was between 2 and 3 months. Liver failure was reversible in one patient."

Gives the latency from exposure to failure and records that reversal is possible but was the exception in this series.

PMID:21038416 REFUTE In Vitro

"Therapeutic doses of VPA inhibited human cellular proliferation and high doses caused nonapoptotic cell death, which was not mediated through mitochondrial DNA depletion, mutation, or a defect of fatty acid metabolism."

Marked REFUTE against the intuitive mechanism that valproate acts by worsening the mitochondrial DNA depletion. All three obvious routes were tested and excluded, which is why this node attributes the toxicity to impaired regeneration instead.

+ 1 more reference

✶

Histopathology

1

Characteristic Alpers liver histopathology

Liver biopsy or post-mortem histology shows a recognized constellation rather than a single lesion: microvesicular steatosis, bile ductular proliferation, hepatocyte dropout, bridging fibrosis or cirrhosis, collapse of liver cell plates, disturbed lobular architecture, regenerative nodules, and oncocytic change in hepatocytes spared by the steatosis. Two of these features together form part of the diagnostic criteria for the syndrome, which is why this is curated as diagnostic rather than descriptive.

Show evidence (1 reference)

PMID:28471437 SUPPORT Human Clinical

"Diagnostic criteria for Alpers syndrome include characteristic liver histopathological changes, namely two of the following: microvesicular steatosis, bile ductular proliferation, hepatocyte dropout"

States the two-of-the-following rule and the first several features, which is what makes this a diagnostic criterion rather than an incidental finding. The quote stops short of the full list because the cached full text line-wraps cirrhosis across a hyphen, so the remaining features are given in the description rather than quoted.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

9

Digestive 1

Hepatic Failure VERY_FREQUENT HP:0001399

Show evidence (2 references)

PMID:21038416 SUPPORT Human Clinical

"AHS is a neurometabolic disorder associated with an increased risk of developing fatal VPA hepatotoxicity."

Establishes hepatic vulnerability as an intrinsic feature of the syndrome rather than only a drug effect.

PMID:20301791 SUPPORT Human Clinical

"Early-onset disease (prior to age 12 years): Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features. This group has the worst prognosis."

Liver involvement is named first among the most common features of the early-onset group, which supports a very frequent band.

Musculoskeletal 1

Hypotonia VERY_FREQUENT HP:0001252

Show evidence (2 references)

PMID:28471437 SUPPORT Human Clinical

"The majority presented with global developmental delay (n=24/24, 100%), hypotonia (n=22/23, 96%) and faltering growth (n=24/27, 89%)."

Hypotonia in 22 of 23 assessable patients, which is 96 percent and supports the very frequent band directly rather than by inference from a qualitative statement.

PMID:20301791 SUPPORT Human Clinical

"Early-onset disease (prior to age 12 years): Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features. This group has the worst prognosis."

Names hypotonia among the most common features of the early-onset group, which is the group this entry models.

Nervous System 4

Intractable Focal Seizures VERY_FREQUENT Focal-onset seizure HP:0007359

Show evidence (2 references)

PMID:20138553 SUPPORT Human Clinical

"All were given VPA due to intractable partial seizures."

All four patients in the series had intractable partial seizures, which supports a very frequent band.

PMID:20301791 SUPPORT Human Clinical

"Early-onset disease (prior to age 12 years): Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features. This group has the worst prognosis."

Names seizures among the most common features of the early-onset group.

Developmental Regression VERY_FREQUENT HP:0002376

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:20301791 SUPPORT Human Clinical

"Early-onset disease (prior to age 12 years): Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features. This group has the worst prognosis."

Characterizes the early-onset group this entry models and its prognosis. Marked PARTIAL because the abstract lists liver involvement, feeding difficulties, seizures, hypotonia and weakness rather than naming regression, so the regression claim rests on the MONDO definition of the triad rather than on this quote.

Ataxia HP:0001251

Show evidence (1 reference)

PMID:30021052 SUPPORT Human Clinical

"We believe interneuron and Purkinje cell pathology underpins the clinical development of seizures and ataxia seen in Alpers' syndrome."

Ties the ataxia to Purkinje cell pathology in the same sentence that ties the seizures to interneuron pathology. No frequency band is assigned, because neither cited source quantifies how often ataxia is present in the early-onset group.

Global Developmental Delay VERY_FREQUENT HP:0001263

Show evidence (1 reference)

PMID:28471437 SUPPORT Human Clinical

"The majority presented with global developmental delay (n=24/24, 100%), hypotonia (n=22/23, 96%) and faltering growth (n=24/27, 89%)."

Global developmental delay in 24 of 24 assessable patients, which supports the very frequent band directly.

Growth 1

Failure to Thrive VERY_FREQUENT HP:0001508

Show evidence (1 reference)

PMID:28471437 SUPPORT Human Clinical

"The majority presented with global developmental delay (n=24/24, 100%), hypotonia (n=22/23, 96%) and faltering growth (n=24/27, 89%)."

Faltering growth in 24 of 27 patients, which is 89 percent and supports the very frequent band directly.

Other 2

Status Epilepticus FREQUENT HP:0002133

Show evidence (2 references)

PMID:28471437 SUPPORT Human Clinical

"Myoclonic 13/19 (68%) Status epilepticus 13/19 (68%) Epilepsia partialis continua 11/19 (58%)"

Status epilepticus in 13 of 19 patients, which is 68 percent and sits in the FREQUENT band. The adjacent rows are included because the figure alone is a bare table cell; the span also shows the seizure-type profile this phenotype sits inside.

PMID:28471437 SUPPORT Human Clinical

"The main causes of death were liver failure (13/22), sepsis (5/22), and status epilepticus (4/22)."

Establishes status epilepticus as a direct cause of death rather than only a severity marker, and puts it third behind liver failure, which is why the hepatic arm of this entry carries the prognosis.

Epilepsia Partialis Continua FREQUENT HP:0012847

Show evidence (1 reference)

PMID:20138553 SUPPORT Human Clinical

"Three of the patients had developed epilepsia partialis continua."

Three of four patients, which supports a frequent rather than very frequent band given the small series.

🧬

Genetic Associations

1

POLG

Gene: POLG hgnc:9179 relationship_type: CAUSATIVE

Show evidence (3 references)

PMID:21038416 SUPPORT Human Clinical

"Rare mutations in POLG, which codes for the mitochondrial DNA polymerase γ (polγ), cause Alpers-Huttenlocher syndrome (AHS)."

States the gene-disease relationship directly and names the enzyme the gene encodes.

PMID:20138553 SUPPORT Human Clinical

"POLG mutations have been observed in every ethnic group studied to date"

Supports the absence of an ancestry restriction, which is the basis for the testing recommendation not being limited by population.

PMID:20138553 SUPPORT Human Clinical

"Molecular studies revealed homozygous p.R597W or p.A467T mutations in two patients. The other two patients showed compound heterozygous mutations, p.A467T/p.Q68X and p.L83P/p.G888S."

Names the specific recurrent variants observed in patients who went on to develop valproate hepatotoxicity.

💊

Medical Actions

4

Avoidance of Sodium Valproate

Action: Supportive Care NCIT:C15747

The single most consequential management decision in this disease, and it is a decision not to treat with a particular drug rather than to treat with one. Valproate can precipitate fatal liver failure at any stage of the illness, so the avoidance is absolute rather than dose-limited or stage-limited. Because the seizures that prompt valproate are exactly the seizures this disease produces, the avoidance only works if the diagnosis is suspected before the prescription is written, which is what makes the testing question in the discussions a clinical rather than an academic one.

Mechanism Target:

INHIBITS Valproate-Precipitated Fulminant Hepatic Failure

Show evidence (2 references)

PMID:20138553 SUPPORT Human Clinical

"VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate liver failure"

The direct basis for the avoidance, and for its being unconditional on disease stage.

PMID:20301791 SUPPORT Other

"Agents/circumstances to avoid: Valproic acid (Depakene®) and sodium divalproate (divalproex) (Depakote®) because of the risk of precipitating and/or accelerating liver disease."

The GeneReviews agents-to-avoid statement, which names both the drug and its salt form and gives the reason. This is the formal management recommendation behind this record, and it says accelerating as well as precipitating, which covers the patient who already has liver disease when the drug is considered.

Liver Enzyme Surveillance

Action: Supportive Care NCIT:C15747

Because the hepatic arm can move fast and can be triggered by a new medication, monitoring is scheduled rather than reactive. Liver enzymes are followed every three months or as clinically indicated, and liver function is rechecked specifically after any new antiseizure medication is introduced. That last clause is the one that matters most here: it converts the general valproate warning into a standing check on every subsequent drug decision, in a disease where seizure control keeps forcing new drug decisions.

Mechanism Target:

MODULATES Hepatocellular Dysfunction and Failure

Show evidence (1 reference)

PMID:20301791 SUPPORT Other

"monitoring of liver enzymes every three months or as clinically indicated; monitoring of epilepsy with repeat liver function tests after introduction of any new anti-seizure medication."

Gives both the routine interval and the event-triggered recheck after any new antiseizure medication, which is the specific surveillance behaviour this record asserts.

POLG Genotyping Before Valproate Exposure

Action: Genetic Testing NCIT:C15709

Genetic testing used as a preventive intervention rather than only as a diagnostic one. Sequencing POLG before starting valproate in a child with intractable seizures identifies those in whom the drug is dangerous, and the same logic extends beyond this syndrome: heterozygous POLG variation carries a substantially increased risk of valproate liver injury, with a reported odds ratio of 23.6, even in people who do not have the disease.

Mechanism Target:

INHIBITS Valproate-Precipitated Fulminant Hepatic Failure

Show evidence (2 references)

PMID:21038416 SUPPORT Human Clinical

"prospective genetic testing of POLG will identify individuals at high risk of this potentially fatal consequence of treatment"

States the preventive value of prospective genotyping in the authors' own terms.

PMID:21038416 SUPPORT Human Clinical

"Heterozygous genetic variation in POLG was strongly associated with VPA-induced liver toxicity"

Establishes that the risk extends to heterozygous carriers, which is the basis for extending testing beyond suspected Alpers-Huttenlocher syndrome. The reported odds ratio of 23.6 appears in the same sentence of the source, inside a parenthetical that is omitted from the quote.

Non-Valproate Antiseizure Therapy and Supportive Care

Action: Supportive Care NCIT:C15747

Seizure control is attempted with agents other than valproate, alongside supportive management of the hepatic and neurological disease. Control is characteristically poor, which is what the word intractable in the phenotype is doing, and no therapy modifies the underlying replication defect.

Mechanism Target:

MODULATES Intractable Focal Epilepsy and Epilepsia Partialis Continua

Show evidence (1 reference)

PMID:20138553 SUPPORT Human Clinical

"All were given VPA due to intractable partial seizures."

Establishes that the seizures are intractable, which is what necessitates alternative agents. Marked PARTIAL because the source documents the intractability and the valproate exposure rather than the efficacy of alternatives.

🔬

Biochemical Markers

2

Blood and cerebrospinal fluid lactate (INCREASED)

Context: Raised lactate is the expected consequence of a respiratory chain that cannot accept electrons fast enough, so pyruvate is shunted to lactate instead. It is useful as a pointer rather than as a test: it was elevated in blood in only about three-fifths of an early-onset cohort at presentation and in cerebrospinal fluid in fewer still, so a normal lactate does not exclude the disease. It is measured here as a marker of the bioenergetic node upstream, not as a diagnostic criterion.

Show evidence (1 reference)

PMID:28471437 SUPPORT Human Clinical

"Laboratory investigations at presentation revealed increased lactate in blood in 60% ( n = 12/20) and in cerebrospinal fluid in 40% ( n = 2/5)."

Quantifies the elevation and, just as importantly, its limits: 12 of 20 in blood means a normal value is common enough that lactate cannot rule the disease out.

Hepatic aminotransferases (INCREASED)

Context: Transaminase elevation is the laboratory face of the hepatic arm and was present in most of an early-onset cohort at presentation. It is also the measure that surveillance tracks, which is why it appears both here and in the liver-enzyme monitoring treatment record.

Show evidence (1 reference)

PMID:28471437 SUPPORT Human Clinical

"Hepatic aminotransferases were increased in 13/20 cases"

Gives the proportion with elevated transaminases at presentation in the early-onset cohort.

🔬

Diagnosis

2

POLG Sequencing

Molecular diagnosis by sequencing POLG. In this disease the test is time-critical in an unusual way: its value is greatest before treatment rather than after, because a result that arrives after valproate has been started may arrive after the damage.

Genetic Testing NCIT:C15709

Show evidence (2 references)

PMID:20138553 SUPPORT Human Clinical

"Molecular studies revealed homozygous p.R597W or p.A467T mutations in two patients. The other two patients showed compound heterozygous mutations, p.A467T/p.Q68X and p.L83P/p.G888S."

Demonstrates sequencing as the diagnostic modality and the biallelic results it yields.

PMID:20301791 SUPPORT Other

"Establishing the diagnosis of a POLG-related disorder relies on clinical findings and the identification of biallelic POLG pathogenic variants on molecular genetic testing"

The GeneReviews diagnostic statement. It is worth noting that the diagnosis is defined as clinical findings plus biallelic variants together, not by genotype alone, which is why this entry keeps the electroclinical and hepatic features as part of the diagnostic picture rather than treating sequencing as sufficient on its own.

Electroencephalography

Recording is used both to characterize the seizures and as a diagnostic clue, since early predominance of epileptiform discharges over the occipital region is common in POLG-related epilepsy. The findings vary between patients and between stages, so the occipital pattern supports the diagnosis when present but does not exclude it when absent.

Electroencephalography NCIT:C38054

Show evidence (2 references)

PMID:20138553 SUPPORT Human Clinical

"early predominance of epileptiform discharges over the occipital region is common in POLG-induced epilepsy"

The diagnostic clue this record describes.

PMID:20138553 SUPPORT Human Clinical

"the EEG and MRI findings varying between patients and stages of the disease"

The caveat that limits the sensitivity of the finding, which is why the description says it supports but does not exclude.

📈

Progression

3

Onset with regression and intractable seizures

Age: Early childhood

The neurological presentation usually precedes the hepatic one. A previously normal child begins to lose skills and develops seizures that do not respond to medication, often escalating to epilepsia partialis continua.

Show evidence (1 reference)

PMID:20138553 SUPPORT Human Clinical

"All were given VPA due to intractable partial seizures. Three of the patients had developed epilepsia partialis continua."

Documents the seizure phenotype at the point of presentation, before liver involvement had declared itself.

Hepatic failure, spontaneous or valproate-precipitated

Age: Weeks to months after the neurological presentation

Liver failure completes the triad. Where valproate has been given, the interval from exposure to failure has been two to three months. The early onset group carries the worst prognosis of the POLG continuum.

Show evidence (2 references)

PMID:20138553 SUPPORT Human Clinical

"The time from VPA exposure to liver failure was between 2 and 3 months. Liver failure was reversible in one patient."

Gives the observed interval and the exceptional case of reversibility.

PMID:20301791 SUPPORT Human Clinical

"Early-onset disease (prior to age 12 years): Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features. This group has the worst prognosis."

Establishes that the early-onset group modelled here has the worst prognosis of the POLG spectrum.

Death, usually in early childhood

Age: Median about sixteen months from birth, about five months from onset

The disease is fatal and it is fatal quickly. In an early-onset cohort the median age at death was under a year and a half, and the median interval from first symptom to death was about five months, with earlier onset predicting shorter survival. Liver failure is the leading cause of death, ahead of sepsis and status epilepticus, which is why an entry organized around an epilepsy carries its prognosis on the hepatic arm.

Show evidence (3 references)

PMID:28471437 SUPPORT Human Clinical

"Median age at death was 15.8 months (range 1.0 to 184.6 months), whereas median time from disease onset to death was 4.9 months (range 0.5 to 181.2 months)."

Gives both survival measures. The very wide ranges are worth noting: the median describes the early-onset centre of the distribution, not every patient.

PMID:28471437 SUPPORT Human Clinical

"The main causes of death were liver failure (13/22), sepsis (5/22), and status epilepticus (4/22)."

Ranks the causes of death, putting liver failure well ahead of the neurological one, which is the empirical basis for treating the hepatic arm as prognosis-determining.

PMID:28471437 SUPPORT Human Clinical

"Median survival time of patients with disease onset ≤ 12 months was 3.6 months ( range 0.5 –181) compared to 10 months (range 1.4–82) for those with disease onset"

Shows that earlier onset predicts shorter survival within the early-onset group itself, which sharpens the age-phenotype correlation the GeneReviews chapter states at spectrum level.

📊

Prevalence

1

Worldwide

Unknown Rare

No population rate is available for Alpers-Huttenlocher syndrome specifically in the sources cited here. Orphanet classifies the entity as rare. What the literature does establish is that POLG variants are not confined to any ancestry group, which bears on testing policy even though it does not give a rate. The prevalence_class is therefore the qualitative RARE tier rather than a numeric band.

Show evidence (1 reference)

PMID:20138553 SUPPORT Human Clinical

"POLG mutations have been observed in every ethnic group studied to date"

Supports the absence of an ancestry restriction. Marked PARTIAL because it constrains the distribution without providing a rate.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Alpers-Huttenlocher Syndrome:

MELAS Syndrome MONDO:0010789

Overlapping Features The other mitochondrial disease that presents with seizures and posterior cortical involvement in a child, and which shares the occipital emphasis seen here. The distinction is mechanistic and inheritance-based: MELAS arises from a maternally inherited mitochondrial DNA point mutation, this syndrome from biallelic nuclear POLG variants causing depletion of the mitochondrial genome.

Distinguishing Features

Maternally inherited mitochondrial DNA point mutation rather than autosomal recessive nuclear POLG variants.
Stroke-like episodes crossing vascular territories rather than epilepsia partialis continua.
Lactic acidosis and ragged-red fibres on muscle biopsy are characteristic.
Hepatic failure is not a defining feature.

Show evidence (1 reference)

PMID:20301791 SUPPORT Human Clinical

"POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined before the molecular basis was known."

Supports that molecular definition is what separates these clinically overlapping mitochondrial presentations. Marked PARTIAL because the source addresses the POLG spectrum rather than comparing it with MELAS directly.

Rasmussen Subacute Encephalitis MONDO:0016019

Overlapping Features The main non-metabolic cause of epilepsia partialis continua with cognitive decline in a child, and therefore the differential that matters at the bedside when a child presents with continuous focal seizures and is losing skills.

Distinguishing Features

Unilateral hemispheric involvement with progressive hemiatrophy rather than a bilateral metabolic process.
Inflammatory histopathology with T-cell infiltrates and microglial nodules.
No hepatic involvement.
Immunotherapy and hemispherectomy are the treatment framework rather than avoidance of a hepatotoxic drug.

Show evidence (1 reference)

PMID:20138553 SUPPORT Human Clinical

"POLG gene testing should be considered in any child or adolescent who presents or develops intractable seizures with or without status epilepticus or epilepsia partialis"

The recommendation is framed around exactly the presentation this differential shares, which is why POLG testing is proposed for the whole presenting syndrome rather than only for suspected cases.

Non-POLG Mitochondrial DNA Depletion Syndromes

Overlapping Features Hepatocerebral mitochondrial DNA depletion can also arise from variants in DGUOK, MPV17 and TWNK among others, producing a similar combination of liver and brain disease. Separation is by gene. No MONDO disease_term is bound because this names a group of separate entities rather than one.

Distinguishing Features

Causative variants in a gene other than POLG.
Seizure phenotype is generally less prominent than in POLG disease, with liver disease often dominating.
Epilepsia partialis continua and the occipital electrographic predominance are not characteristic.

Show evidence (1 reference)

PMID:20301791 SUPPORT Human Clinical

"POLG-related disorders can therefore be considered an overlapping spectrum of disease presenting from early childhood to late adulthood."

Establishes the POLG-defined boundary of the spectrum this entry sits in. Marked PARTIAL because the source does not enumerate the other depletion-syndrome genes.

{ }

Source YAML

click to show

name: Alpers-Huttenlocher Syndrome
creation_date: "2026-08-05T00:00:00Z"
category: Complex
description: >-
  A severe childhood mitochondrial disease that kills a brain and a liver at the
  same time, from the same lesion. The gene is POLG, which encodes the only
  polymerase the mitochondrion has for copying its own small genome; when both
  copies fail, mitochondrial DNA is not replaced as it turns over, and the
  tissues that need the most mitochondria run out first. Clinically that shows up
  as a triad: a toddler or young child who had been developing normally starts
  losing skills, develops seizures that will not stop and often become epilepsia
  partialis continua, and then the liver fails. The epileptiform activity has an
  odd and consistent preference for the occipital region, which nobody has
  explained. And there is a trap built into the disease: sodium valproate, one of
  the drugs a neurologist would naturally reach for in intractable seizures, can
  precipitate fatal liver failure in these children at any stage of the illness.
  That is why this entry treats a drug as part of the pathophysiology rather than
  only as a treatment.
parents:
  - Epilepsy
  - Mitochondrial Disease
  - Neurological Disease
synonyms:
  - AHS
  - Alpers syndrome
  - Alpers disease
  - progressive sclerosing poliodystrophy
  - mitochondrial DNA depletion syndrome 4A
classifications:
  harrisons_chapter:
    - classification_value: NEUROLOGIC
      notes: >-
        A POLG-related mitochondrial disorder presenting as a cerebrohepatopathy,
        managed by neurology together with hepatology and metabolic medicine.
disease_term:
  preferred_term: Alpers-Huttenlocher syndrome
  term:
    id: MONDO:0008758
    label: mitochondrial DNA depletion syndrome 4a
mappings:
  mondo_mappings:
    - term:
        id: MONDO:0008758
        label: mitochondrial DNA depletion syndrome 4a
      mapping_predicate: skos:exactMatch
      mapping_source: MONDO
      mapping_justification: >-
        MONDO:0008758 is the entity for Alpers-Huttenlocher syndrome, carried
        under the molecular label mitochondrial DNA depletion syndrome 4a and
        defined as the cerebrohepatopathy characterized by the triad of
        progressive developmental regression, intractable seizures, and hepatic
        failure. The clinical eponym is used as the entry name and preferred_term
        because that is what the literature and the clinic use.
references:
  - reference: PMID:20301791
    title: POLG-Related Disorders.
    tags:
      - GeneReviews
  - reference: PMID:21038416
    title: >-
      Polymerase gamma gene POLG determines the risk of sodium valproate-induced
      liver toxicity.
  - reference: PMID:20138553
    title: >-
      POLG DNA testing as an emerging standard of care before instituting
      valproic acid therapy for pediatric seizure disorders.
notes: >-
  Scope. This entry models Alpers-Huttenlocher syndrome, the early-onset severe
  end of the POLG-related disease continuum. It does not model the juvenile and
  adult POLG phenotypes (ataxia-neuropathy spectrum, progressive external
  ophthalmoplegia, MEMSA), which share the same gene and much of the same
  molecular mechanism but differ in age, tempo, prognosis and organ involvement.
  Those are better served by their own entries or by a POLG grouping; the
  GeneReviews chapter cited here treats them all as one continuum, and this entry
  deliberately takes only the early-onset segment of it.

  Why a drug is in the pathograph. The node for valproate-precipitated liver
  failure is not a treatment complication filed under adverse effects. It is a
  causal path that this disease routinely takes, it is reached through ordinary
  competent care rather than through error, and it changes the outcome. Modelling
  it as a pathophysiology node makes the iatrogenic arm queryable alongside the
  intrinsic one, which is the point. The corresponding treatment record is an
  avoidance rather than an administration, which is unusual but correct here.

  Module conformance note. Two nodes conform to
  epilepsy_excitation_inhibition_imbalance, at the excitation-inhibition node and
  at the recurrent-seizure node. The first of those was added on evidence rather
  than by default, and the reasoning is worth recording because it was initially
  decided the other way. The obvious objection is that the proximal lesion here
  is replicative and bioenergetic, not a channel or synaptic defect, so an
  excitation-inhibition claim looked like a category error. Quantitative
  post-mortem work settles it: the respiratory chain deficiency falls
  preferentially on inhibitory GABAergic interneurons, and those cells are
  depleted. Losing inhibitory neurons selectively is an excitation-inhibition
  imbalance in the most literal sense; the route to it happens to be metabolic
  rather than electrical, and the module node does not require a particular
  route. Conformance is still not claimed at the module's
  ion-channel-and-synaptic-dysfunction node, because nothing here implicates a
  channel.

  Sourcing note. Drafted from the primary literature, then cross-checked against
  a deep-research report generated with the falcon provider (Edison Scientific),
  committed as research/Alpers-Huttenlocher_Syndrome-deep-research-falcon.md. It
  contributed no snippets, but unlike the other entries in this batch it changed
  the entry materially, by pointing at a paper the first draft had missed.

  The first draft said flatly that the occipital predominance had no accepted
  explanation. That was wrong, or at least out of date. The report surfaced a
  quantitative post-mortem study of thirteen Alpers brains showing that the
  respiratory chain deficiency is not uniform across cortex but concentrated in
  inhibitory interneurons and pyramidal neurons of occipital cortex and in
  Purkinje cells, with those populations depleted. Fetching and verifying that
  source changed three things: the cortical node was rewritten around the
  cellular selectivity rather than around generic degeneration, module
  conformance at the excitation-inhibition node was added where the draft had
  explicitly declined it, and the occipital knowledge gap was narrowed from why
  this lobe to why these cells in this lobe. The same source supplied the ataxia
  phenotype, via the Purkinje cell arm.

  Two figures the report gives that this entry does not assert: that more than
  90% of classic cases are attributed to biallelic POLG variants, and the
  status-epilepticus burden from a 195-patient multinational cohort. Both come
  from full-text tables rather than from anything quotable in the abstracts
  fetched here, so they are left out rather than paraphrased into evidence.

  A cross-reference worth keeping. The occipital predominance of the epileptiform
  activity in this disease is curated as a knowledge gap. Two other entries in
  this knowledge base, Childhood_Occipital_Visual_Epilepsy and
  Photosensitive_Occipital_Lobe_Epilepsy, model occipital-onset epilepsies with
  no shared etiology whatsoever. Whether occipital cortex has a general
  vulnerability that these unrelated diseases all expose is a question none of
  the three entries can answer alone, and it is raised in the discussion here
  because this is the entry where the vulnerability is least explicable by
  anything local.
inheritance:
  - name: Autosomal recessive
    description: >-
      Biallelic pathogenic variants in POLG. Both alleles must be affected;
      heterozygous carriers do not develop the syndrome, although heterozygous
      POLG variation is separately and importantly associated with susceptibility
      to valproate-induced liver injury in people who do not have the disease at
      all.
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Molecular studies revealed homozygous p.R597W or p.A467T mutations in
          two patients. The other two patients showed compound heterozygous
          mutations, p.A467T/p.Q68X and p.L83P/p.G888S.
        explanation: >-
          Four patients, two homozygous and two compound heterozygous, which is
          the biallelic pattern of autosomal recessive inheritance.
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          If both parents are known to be heterozygous for a POLG pathogenic
          variant, each sib of an affected individual has at conception a 25%
          chance of inheriting biallelic pathogenic variants and being affected,
          a 50% chance of being heterozygous, and a 25% chance of inheriting
          neither of the familial POLG pathogenic variants.
        explanation: >-
          The GeneReviews recurrence-risk statement, which is the practical
          content of the inheritance mode for a family. The 25/50/25 split is
          what autosomal recessive means at the bedside, and it is stated here
          rather than left to be inferred from the mode alone.
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Heterozygous sibs of a proband with an autosomal recessive POLG-related
          disorder are typically asymptomatic.
        explanation: >-
          Confirms that carriers do not have the syndrome, which is the claim this
          block makes and which has to be stated carefully here, because
          heterozygous POLG variation is separately associated with valproate
          hepatotoxicity risk. Asymptomatic for the disease is not the same as
          free of drug risk.
genetic:
  - name: POLG
    gene_term:
      preferred_term: POLG
      term:
        id: hgnc:9179
        label: POLG
    relationship_type: CAUSATIVE
    notes: >-
      POLG encodes the catalytic subunit of DNA polymerase gamma, which is the
      only polymerase that replicates mitochondrial DNA. That exclusivity is what
      makes the gene so consequential: there is no redundant enzyme to
      compensate. Recurrent pathogenic variants include p.A467T and p.R597W,
      found homozygous in reported cases, with compound heterozygosity common;
      p.Q1236H is the common variant implicated separately in valproate
      hepatotoxicity risk. Variants have been found in every ethnic group
      examined, which matters practically because it removes ancestry as a reason
      not to test.
    evidence:
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Rare mutations in POLG, which codes for the mitochondrial DNA
          polymerase γ (polγ), cause Alpers-Huttenlocher syndrome (AHS).
        explanation: >-
          States the gene-disease relationship directly and names the enzyme the
          gene encodes.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          POLG mutations have been observed in every ethnic group studied to
          date
        explanation: >-
          Supports the absence of an ancestry restriction, which is the basis for
          the testing recommendation not being limited by population.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Molecular studies revealed homozygous p.R597W or p.A467T mutations in
          two patients. The other two patients showed compound heterozygous
          mutations, p.A467T/p.Q68X and p.L83P/p.G888S.
        explanation: >-
          Names the specific recurrent variants observed in patients who went on
          to develop valproate hepatotoxicity.
pathophysiology:
  - name: Biallelic Loss of DNA Polymerase Gamma Function
    biological_scale: MOLECULAR
    description: >-
      The proximal lesion. Both POLG alleles carry pathogenic variants, so the
      catalytic subunit of polymerase gamma is impaired in fidelity, processivity
      or abundance. Because polymerase gamma is the sole replicative polymerase
      of the mitochondrial genome, there is no backup enzyme, and the consequence
      of the lesion falls entirely on mitochondrial DNA rather than being buffered
      by the nuclear replication machinery.
    genes:
      - preferred_term: POLG
        term:
          id: hgnc:9179
          label: POLG
    molecular_functions:
      - preferred_term: DNA-directed DNA polymerase activity
        term:
          id: GO:0003887
          label: DNA-directed DNA polymerase activity
        modifier: DECREASED
    downstream:
      - target: Failure of Mitochondrial DNA Replication
    evidence:
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Rare mutations in POLG, which codes for the mitochondrial DNA
          polymerase γ (polγ), cause Alpers-Huttenlocher syndrome (AHS).
        explanation: >-
          Establishes the causal relationship between loss of this specific
          enzyme and the syndrome.
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          This was principally due to the p.Q1236H substitution which compromised
          polγ function in yeast.
        explanation: >-
          Functional demonstration in a model system that a POLG substitution
          compromises the enzyme, supporting loss of function as the mechanism
          rather than a purely statistical association.
  - name: Failure of Mitochondrial DNA Replication
    biological_scale: MOLECULAR
    description: >-
      Mitochondrial DNA is not a static archive; it turns over and must be
      continually re-replicated even in cells that never divide. With polymerase
      gamma impaired, replication cannot keep pace with that turnover, which is
      why a replication defect produces a quantitative loss of genome copies
      rather than only a mutational burden.
    biological_processes:
      - preferred_term: mitochondrial DNA replication
        term:
          id: GO:0006264
          label: mitochondrial DNA replication
        modifier: DECREASED
    downstream:
      - target: Tissue Mitochondrial DNA Depletion
    evidence:
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Rare mutations in POLG, which codes for the mitochondrial DNA
          polymerase γ (polγ), cause Alpers-Huttenlocher syndrome (AHS).
        explanation: >-
          Names the enzyme as the mitochondrial DNA polymerase, which is what
          makes replication of that genome the process this node describes.
  - name: Tissue Mitochondrial DNA Depletion
    biological_scale: CELLULAR
    description: >-
      Loss of mitochondrial genome copy number in affected tissues, most
      prominently brain and liver. This is the feature that places the disease in
      the mitochondrial DNA depletion syndromes and gives the MONDO entity its
      molecular name. The tissue selectivity is not fully explained by energy
      demand alone, but brain and liver are where the clinical disease appears.
    locations:
      - preferred_term: liver
        term:
          id: UBERON:0002107
          label: liver
    cell_types:
      - preferred_term: hepatocyte
        term:
          id: CL:0000182
          label: hepatocyte
      - preferred_term: neuron
        term:
          id: CL:0000540
          label: neuron
    downstream:
      - target: Respiratory Chain Deficiency and Cellular Energy Failure
    evidence:
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          POLG-related disorders comprise a continuum of overlapping phenotypes
          that were clinically defined before the molecular basis was known.
        explanation: >-
          Supports that a single molecular lesion underlies phenotypes that were
          separately described clinically. Marked PARTIAL because it establishes
          the shared molecular basis without quantifying depletion in specific
          tissues.
  - name: Respiratory Chain Deficiency and Cellular Energy Failure
    biological_scale: CELLULAR
    description: >-
      Because the mitochondrial genome encodes core subunits of the respiratory
      chain, losing genome copies means losing the capacity to build those
      complexes, and oxidative phosphorylation falls. The cells that decompensate
      first are the ones with the least metabolic slack, which is the general
      explanation for why a systemic replication defect presents as a brain and
      liver disease.
    cell_types:
      - preferred_term: neuron
        term:
          id: CL:0000540
          label: neuron
      - preferred_term: hepatocyte
        term:
          id: CL:0000182
          label: hepatocyte
    downstream:
      - target: Selective Interneuron and Pyramidal Neuron Loss in Occipital Cortex
      - target: Hepatocellular Dysfunction and Failure
      - target: Progressive Developmental Regression
    evidence:
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          POLG-related disorders can therefore be considered an overlapping
          spectrum of disease presenting from early childhood to late adulthood.
        explanation: >-
          Supports a shared underlying mechanism expressed across a range of
          severities and ages. Marked PARTIAL because the abstract does not
          itself measure respiratory chain function.
  - name: Selective Interneuron and Pyramidal Neuron Loss in Occipital Cortex
    biological_scale: TISSUE
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
    description: >-
      The energy failure does not fall evenly on the cortex, and quantitative
      post-mortem work says where it lands. In the largest series of Alpers
      brains examined this way, severe respiratory chain deficiency involving
      complex I, and to a lesser extent complex IV, was found in inhibitory
      interneurons and pyramidal neurons of the occipital cortex and in cerebellar
      Purkinje cells, with reduced densities of those same populations. That is
      the mechanistic content behind the syndrome's otherwise puzzling occipital
      emphasis, and it is why this node conforms to the module's
      excitation-inhibition node rather than only to a generic degeneration:
      losing inhibitory interneurons preferentially is an
      excitation-inhibition imbalance in the most literal sense, arrived at
      through bioenergetic failure instead of through a channel defect. The same
      finding accounts for the cerebellar signs, since Purkinje cells are the sole
      output of the cerebellar cortex. The classical description of the disease as
      a progressive sclerosing poliodystrophy refers to this grey-matter loss.
    locations:
      - preferred_term: occipital lobe
        term:
          id: UBERON:0002021
          label: occipital lobe
      - preferred_term: cerebellar cortex
        term:
          id: UBERON:0002129
          label: cerebellar cortex
    cell_types:
      - preferred_term: inhibitory interneuron
        term:
          id: CL:0000099
          label: interneuron
      - preferred_term: GABAergic neuron
        term:
          id: CL:0000617
          label: GABAergic neuron
      - preferred_term: Purkinje cell
        term:
          id: CL:0000121
          label: Purkinje cell
    biological_processes:
      - preferred_term: mitochondrial ATP synthesis coupled electron transport
        term:
          id: GO:0042775
          label: mitochondrial ATP synthesis coupled electron transport
        modifier: DECREASED
    downstream:
      - target: Intractable Focal Epilepsy and Epilepsia Partialis Continua
    evidence:
      - reference: PMID:30021052
        reference_title: >-
          Dissecting the neuronal vulnerability underpinning Alpers' syndrome: a
          clinical and neuropathological study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Quantitative immunofluorescence showed severe respiratory chain
          deficiencies involving mitochondrial respiratory chain subunits of
          complex I and, to a lesser extent, complex IV in inhibitory interneurons
          and pyramidal neurons in the occipital cortex and in Purkinje cells of
          the cerebellum. Diminished densities of these neuronal populations were
          also observed.
        explanation: >-
          The quantitative post-mortem basis for every claim in this node: which
          complexes fail, which cell populations they fail in, that those
          populations include inhibitory interneurons, that the cortical site is
          occipital, and that the cells are actually lost rather than merely
          impaired.
      - reference: PMID:30021052
        reference_title: >-
          Dissecting the neuronal vulnerability underpinning Alpers' syndrome: a
          clinical and neuropathological study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We believe interneuron and Purkinje cell pathology underpins the
          clinical development of seizures and ataxia seen in Alpers' syndrome.
        explanation: >-
          The authors' own causal reading, which is what licenses this node's
          downstream edge to the epilepsy and its conformance to the
          excitation-inhibition node of the module. Their framing is a belief
          rather than a demonstration, which the discussion below preserves.
      - reference: PMID:30021052
        reference_title: >-
          Dissecting the neuronal vulnerability underpinning Alpers' syndrome: a
          clinical and neuropathological study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          This study also further highlights the extensive involvement of
          GABAergic neurons in mitochondrial disease.
        explanation: >-
          Identifies the vulnerable interneurons as GABAergic, which is the
          specific inhibitory population whose loss makes this an
          excitation-inhibition imbalance rather than a nonspecific cell loss.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          early predominance of epileptiform discharges over the occipital region
          is common in POLG-induced epilepsy
        explanation: >-
          The electrographic counterpart of the neuropathology, offered by the
          authors as a recognition feature of POLG-related epilepsy. The two
          together are why the occipital localization is modelled as a real
          mechanistic fact rather than an observational quirk.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          the EEG and MRI findings varying between patients and stages of the
          disease
        explanation: >-
          Qualifies the occipital finding: the imaging and electrographic picture
          is not uniform, which is why this node asserts a predominance rather
          than a fixed pattern.
  - name: Intractable Focal Epilepsy and Epilepsia Partialis Continua
    biological_scale: ORGANISM
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
    description: >-
      Focal seizures that do not respond to medication, frequently escalating to
      epilepsia partialis continua, a state of continuous focal motor seizure
      activity that can persist for days or longer. In the reported series most
      children who went on to valproate hepatotoxicity had developed epilepsia
      partialis continua, which is the clinical reason the drug was reached for in
      the first place and is therefore the hinge between the two arms of this
      pathograph.
    downstream:
      - target: Valproate-Precipitated Fulminant Hepatic Failure
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          All were given VPA due to intractable partial seizures. Three of the
          patients had developed epilepsia partialis continua.
        explanation: >-
          Establishes both the intractable focal epilepsy and the frequency of
          epilepsia partialis continua, and shows that the seizures are what led
          to the drug exposure.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          POLG gene testing should be considered in any child or adolescent who
          presents or develops intractable seizures with or without status
          epilepticus or epilepsia partialis
        explanation: >-
          The authors' proposed trigger for testing, which is stated in terms of
          this seizure phenotype.
  - name: Progressive Developmental Regression
    biological_scale: ORGANISM
    description: >-
      Loss of previously acquired skills in a child who had been developing
      normally, which with the seizures and the liver failure completes the
      defining triad. Regression rather than delay is the key observation: these
      children had the skills and lost them, which points to a degenerative
      process rather than a developmental one.
    evidence:
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The age of onset broadly correlates with the clinical phenotype.
        explanation: >-
          Supports that the early-onset presentation this entry models is a
          distinct point on the POLG continuum. Marked PARTIAL because the
          abstract states the age-phenotype relationship rather than describing
          regression itself, which is taken from the MONDO definition of the
          triad.
  - name: Hepatocellular Dysfunction and Failure
    biological_scale: ORGANISM
    description: >-
      Liver failure is the third element of the triad and is frequently what
      determines survival. It can develop as part of the natural history, without
      any drug exposure, which is what distinguishes the intrinsic hepatic arm of
      this pathograph from the valproate-precipitated one downstream of it.
    locations:
      - preferred_term: liver
        term:
          id: UBERON:0002107
          label: liver
    cell_types:
      - preferred_term: hepatocyte
        term:
          id: CL:0000182
          label: hepatocyte
    downstream:
      - target: Valproate-Precipitated Fulminant Hepatic Failure
    evidence:
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          AHS is a neurometabolic disorder associated with an increased risk of
          developing fatal VPA hepatotoxicity.
        explanation: >-
          Names the syndrome as neurometabolic and establishes the hepatic
          vulnerability that both this node and the one downstream of it depend
          on.
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Early-onset disease (prior to age 12 years): Liver involvement, feeding
          difficulties, seizures, hypotonia, and muscle weakness are the most
          common clinical features. This group has the worst prognosis.
        explanation: >-
          Names liver involvement among the most common features of the
          early-onset group, alongside the seizures, which is the co-occurrence
          this pathograph models.
  - name: Valproate-Precipitated Fulminant Hepatic Failure
    biological_scale: ORGANISM
    description: >-
      The iatrogenic arm, and the reason this disease has to be recognized before
      it is treated. Sodium valproate is a reasonable choice for intractable
      focal seizures and is widely used; in a child with POLG disease it can
      precipitate liver failure at any stage of the illness, typically within two
      to three months of starting it, and it is often fatal. What the mechanism is
      not, is as informative as what it is: the toxicity was found not to be
      mediated through mitochondrial DNA depletion, through mutation, or through a
      defect in fatty acid metabolism, which rules out the intuitive explanation
      that valproate simply accelerates the underlying lesion. The finding instead
      implicates impaired liver regeneration, with valproate inhibiting cellular
      proliferation at therapeutic doses and causing non-apoptotic cell death at
      high ones.
    locations:
      - preferred_term: liver
        term:
          id: UBERON:0002107
          label: liver
    cell_types:
      - preferred_term: hepatocyte
        term:
          id: CL:0000182
          label: hepatocyte
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate
          liver failure
        explanation: >-
          The core clinical claim of this node, stated without qualification about
          disease stage, which is what makes the avoidance absolute rather than
          conditional.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The time from VPA exposure to liver failure was between 2 and 3 months.
          Liver failure was reversible in one patient.
        explanation: >-
          Gives the latency from exposure to failure and records that reversal is
          possible but was the exception in this series.
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: REFUTE
        evidence_source: IN_VITRO
        snippet: >-
          Therapeutic doses of VPA inhibited human cellular proliferation and high
          doses caused nonapoptotic cell death, which was not mediated through
          mitochondrial DNA depletion, mutation, or a defect of fatty acid
          metabolism.
        explanation: >-
          Marked REFUTE against the intuitive mechanism that valproate acts by
          worsening the mitochondrial DNA depletion. All three obvious routes were
          tested and excluded, which is why this node attributes the toxicity to
          impaired regeneration instead.
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          These findings implicate impaired liver regeneration in VPA toxicity
        explanation: >-
          The authors' positive conclusion about mechanism, which is what this
          node asserts in place of the refuted depletion explanation.
phenotypes:
  - category: Neurological
    name: Intractable Focal Seizures
    description: >-
      Focal seizures resistant to antiseizure medication, the neurological
      presenting feature in most children.
    phenotype_term:
      preferred_term: Focal-onset seizure
      term:
        id: HP:0007359
        label: Focal-onset seizure
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          All were given VPA due to intractable partial seizures.
        explanation: >-
          All four patients in the series had intractable partial seizures, which
          supports a very frequent band.
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Early-onset disease (prior to age 12 years): Liver involvement, feeding
          difficulties, seizures, hypotonia, and muscle weakness are the most
          common clinical features. This group has the worst prognosis.
        explanation: >-
          Names seizures among the most common features of the early-onset group.
  - category: Neurological
    name: Status Epilepticus
    description: >-
      Seizures that fail to self-terminate, frequently refractory, and one of the
      three main causes of death in this disease alongside liver failure and
      sepsis. It is the endpoint the intractability arm of this pathograph runs
      toward.
    phenotype_term:
      preferred_term: Status epilepticus
      term:
        id: HP:0002133
        label: Status epilepticus
    frequency: FREQUENT
    evidence:
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Myoclonic 13/19 (68%) Status epilepticus 13/19 (68%) Epilepsia partialis
          continua 11/19 (58%)
        explanation: >-
          Status epilepticus in 13 of 19 patients, which is 68 percent and sits in
          the FREQUENT band. The adjacent rows are included because the figure
          alone is a bare table cell; the span also shows the seizure-type profile
          this phenotype sits inside.
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The main causes of death were liver failure (13/22), sepsis (5/22), and
          status epilepticus (4/22).
        explanation: >-
          Establishes status epilepticus as a direct cause of death rather than
          only a severity marker, and puts it third behind liver failure, which is
          why the hepatic arm of this entry carries the prognosis.
  - category: Growth
    name: Failure to Thrive
    description: >-
      Faltering growth, present in the great majority of an early-onset cohort
      and part of the presenting picture alongside the developmental and
      neurological features.
    phenotype_term:
      preferred_term: Failure to thrive
      term:
        id: HP:0001508
        label: Failure to thrive
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The majority presented with global developmental delay (n=24/24, 100%),
          hypotonia (n=22/23, 96%) and faltering growth (n=24/27, 89%).
        explanation: >-
          Faltering growth in 24 of 27 patients, which is 89 percent and supports
          the very frequent band directly.
  - category: Neurological
    name: Epilepsia Partialis Continua
    description: >-
      Continuous focal motor seizure activity, often affecting one limb or one
      side of the face, which may persist for days and is characteristic enough
      to prompt POLG testing.
    phenotype_term:
      preferred_term: Epilepsia partialis continua
      term:
        id: HP:0012847
        label: Epilepsia partialis continua
    frequency: FREQUENT
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Three of the patients had developed epilepsia partialis continua.
        explanation: >-
          Three of four patients, which supports a frequent rather than very
          frequent band given the small series.
  - category: Neurological
    name: Developmental Regression
    description: >-
      Loss of previously acquired developmental skills, one element of the
      defining triad.
    phenotype_term:
      preferred_term: Developmental regression
      term:
        id: HP:0002376
        label: Developmental regression
      clinical_course: PROGRESSIVE
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Early-onset disease (prior to age 12 years): Liver involvement, feeding
          difficulties, seizures, hypotonia, and muscle weakness are the most
          common clinical features. This group has the worst prognosis.
        explanation: >-
          Characterizes the early-onset group this entry models and its prognosis.
          Marked PARTIAL because the abstract lists liver involvement, feeding
          difficulties, seizures, hypotonia and weakness rather than naming
          regression, so the regression claim rests on the MONDO definition of the
          triad rather than on this quote.
  - category: Hepatic
    name: Hepatic Failure
    description: >-
      Liver failure, which may arise in the natural history of the disease or be
      precipitated by valproate exposure, and which frequently determines
      survival.
    phenotype_term:
      preferred_term: Hepatic failure
      term:
        id: HP:0001399
        label: Hepatic failure
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          AHS is a neurometabolic disorder associated with an increased risk of
          developing fatal VPA hepatotoxicity.
        explanation: >-
          Establishes hepatic vulnerability as an intrinsic feature of the
          syndrome rather than only a drug effect.
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Early-onset disease (prior to age 12 years): Liver involvement, feeding
          difficulties, seizures, hypotonia, and muscle weakness are the most
          common clinical features. This group has the worst prognosis.
        explanation: >-
          Liver involvement is named first among the most common features of the
          early-onset group, which supports a very frequent band.
  - category: Neurological
    name: Hypotonia
    description: >-
      Reduced muscle tone, among the most common features of the early-onset POLG
      group and near-universal in cohorts ascertained on early onset.
    phenotype_term:
      preferred_term: Hypotonia
      term:
        id: HP:0001252
        label: Hypotonia
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The majority presented with global developmental delay (n=24/24, 100%),
          hypotonia (n=22/23, 96%) and faltering growth (n=24/27, 89%).
        explanation: >-
          Hypotonia in 22 of 23 assessable patients, which is 96 percent and
          supports the very frequent band directly rather than by inference from
          a qualitative statement.
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Early-onset disease (prior to age 12 years): Liver involvement, feeding
          difficulties, seizures, hypotonia, and muscle weakness are the most
          common clinical features. This group has the worst prognosis.
        explanation: >-
          Names hypotonia among the most common features of the early-onset group,
          which is the group this entry models.
  - category: Neurological
    name: Ataxia
    description: >-
      Cerebellar ataxia, attributed to loss of Purkinje cells, which are the sole
      output neurons of the cerebellar cortex and are among the populations shown
      to carry severe respiratory chain deficiency in this disease.
    phenotype_term:
      preferred_term: Ataxia
      term:
        id: HP:0001251
        label: Ataxia
    evidence:
      - reference: PMID:30021052
        reference_title: >-
          Dissecting the neuronal vulnerability underpinning Alpers' syndrome: a
          clinical and neuropathological study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We believe interneuron and Purkinje cell pathology underpins the
          clinical development of seizures and ataxia seen in Alpers' syndrome.
        explanation: >-
          Ties the ataxia to Purkinje cell pathology in the same sentence that
          ties the seizures to interneuron pathology. No frequency band is
          assigned, because neither cited source quantifies how often ataxia is
          present in the early-onset group.
  - category: Neurological
    name: Global Developmental Delay
    description: >-
      Delay across developmental domains, present in every assessable patient of
      an early-onset POLG cohort. This is recorded separately from developmental
      regression, because delay and loss of acquired skills are different
      observations and the cited cohort reports the former.
    phenotype_term:
      preferred_term: Global developmental delay
      term:
        id: HP:0001263
        label: Global developmental delay
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The majority presented with global developmental delay (n=24/24, 100%),
          hypotonia (n=22/23, 96%) and faltering growth (n=24/27, 89%).
        explanation: >-
          Global developmental delay in 24 of 24 assessable patients, which
          supports the very frequent band directly.
biochemical:
  - name: Blood and cerebrospinal fluid lactate
    presence: INCREASED
    context: >-
      Raised lactate is the expected consequence of a respiratory chain that
      cannot accept electrons fast enough, so pyruvate is shunted to lactate
      instead. It is useful as a pointer rather than as a test: it was elevated in
      blood in only about three-fifths of an early-onset cohort at presentation
      and in cerebrospinal fluid in fewer still, so a normal lactate does not
      exclude the disease. It is measured here as a marker of the bioenergetic
      node upstream, not as a diagnostic criterion.
    biomarker_term:
      preferred_term: lactate
      term:
        id: CHEBI:24996
        label: lactate
    evidence:
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Laboratory investigations at presentation revealed increased lactate in
          blood in 60% ( n = 12/20) and in cerebrospinal fluid in 40% ( n = 2/5).
        explanation: >-
          Quantifies the elevation and, just as importantly, its limits: 12 of 20
          in blood means a normal value is common enough that lactate cannot rule
          the disease out.
  - name: Hepatic aminotransferases
    presence: INCREASED
    context: >-
      Transaminase elevation is the laboratory face of the hepatic arm and was
      present in most of an early-onset cohort at presentation. It is also the
      measure that surveillance tracks, which is why it appears both here and in
      the liver-enzyme monitoring treatment record.
    evidence:
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Hepatic aminotransferases were increased in 13/20 cases
        explanation: >-
          Gives the proportion with elevated transaminases at presentation in the
          early-onset cohort.
histopathology:
  - name: Characteristic Alpers liver histopathology
    description: >-
      Liver biopsy or post-mortem histology shows a recognized constellation
      rather than a single lesion: microvesicular steatosis, bile ductular
      proliferation, hepatocyte dropout, bridging fibrosis or cirrhosis, collapse
      of liver cell plates, disturbed lobular architecture, regenerative nodules,
      and oncocytic change in hepatocytes spared by the steatosis. Two of these
      features together form part of the diagnostic criteria for the syndrome,
      which is why this is curated as diagnostic rather than descriptive.
    diagnostic: true
    evidence:
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Diagnostic criteria for Alpers syndrome include characteristic liver
          histopathological changes, namely two of the following: microvesicular
          steatosis, bile ductular proliferation, hepatocyte dropout
        explanation: >-
          States the two-of-the-following rule and the first several features,
          which is what makes this a diagnostic criterion rather than an
          incidental finding. The quote stops short of the full list because the
          cached full text line-wraps cirrhosis across a hyphen, so the remaining
          features are given in the description rather than quoted.
prevalence:
  - population: Worldwide
    measure_type: UNKNOWN
    prevalence_class: RARE
    notes: >-
      No population rate is available for Alpers-Huttenlocher syndrome
      specifically in the sources cited here. Orphanet classifies the entity as
      rare. What the literature does establish is that POLG variants are not
      confined to any ancestry group, which bears on testing policy even though it
      does not give a rate. The prevalence_class is therefore the qualitative RARE
      tier rather than a numeric band.
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          POLG mutations have been observed in every ethnic group studied to
          date
        explanation: >-
          Supports the absence of an ancestry restriction. Marked PARTIAL because
          it constrains the distribution without providing a rate.
progression:
  - phase: Onset with regression and intractable seizures
    age_range: Early childhood
    notes: >-
      The neurological presentation usually precedes the hepatic one. A previously
      normal child begins to lose skills and develops seizures that do not respond
      to medication, often escalating to epilepsia partialis continua.
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          All were given VPA due to intractable partial seizures. Three of the
          patients had developed epilepsia partialis continua.
        explanation: >-
          Documents the seizure phenotype at the point of presentation, before
          liver involvement had declared itself.
  - phase: Hepatic failure, spontaneous or valproate-precipitated
    age_range: Weeks to months after the neurological presentation
    notes: >-
      Liver failure completes the triad. Where valproate has been given, the
      interval from exposure to failure has been two to three months. The early
      onset group carries the worst prognosis of the POLG continuum.
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The time from VPA exposure to liver failure was between 2 and 3 months.
          Liver failure was reversible in one patient.
        explanation: >-
          Gives the observed interval and the exceptional case of reversibility.
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Early-onset disease (prior to age 12 years): Liver involvement, feeding
          difficulties, seizures, hypotonia, and muscle weakness are the most
          common clinical features. This group has the worst prognosis.
        explanation: >-
          Establishes that the early-onset group modelled here has the worst
          prognosis of the POLG spectrum.
  - phase: Death, usually in early childhood
    age_range: Median about sixteen months from birth, about five months from onset
    notes: >-
      The disease is fatal and it is fatal quickly. In an early-onset cohort the
      median age at death was under a year and a half, and the median interval
      from first symptom to death was about five months, with earlier onset
      predicting shorter survival. Liver failure is the leading cause of death,
      ahead of sepsis and status epilepticus, which is why an entry organized
      around an epilepsy carries its prognosis on the hepatic arm.
    evidence:
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Median age at death was 15.8 months (range 1.0 to 184.6 months), whereas
          median time from disease onset to death was 4.9 months (range 0.5 to
          181.2 months).
        explanation: >-
          Gives both survival measures. The very wide ranges are worth noting:
          the median describes the early-onset centre of the distribution, not
          every patient.
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The main causes of death were liver failure (13/22), sepsis (5/22), and
          status epilepticus (4/22).
        explanation: >-
          Ranks the causes of death, putting liver failure well ahead of the
          neurological one, which is the empirical basis for treating the hepatic
          arm as prognosis-determining.
      - reference: PMID:28471437
        reference_title: >-
          The clinical spectrum and natural history of early-onset diseases due to
          DNA polymerase gamma mutations.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Median survival time of patients with disease onset ≤ 12 months was 3.6
          months ( range 0.5 –181) compared to 10 months (range 1.4–82) for those
          with disease onset
        explanation: >-
          Shows that earlier onset predicts shorter survival within the
          early-onset group itself, which sharpens the age-phenotype correlation
          the GeneReviews chapter states at spectrum level.
treatments:
  - name: Avoidance of Sodium Valproate
    description: >-
      The single most consequential management decision in this disease, and it
      is a decision not to treat with a particular drug rather than to treat with
      one. Valproate can precipitate fatal liver failure at any stage of the
      illness, so the avoidance is absolute rather than dose-limited or
      stage-limited. Because the seizures that prompt valproate are exactly the
      seizures this disease produces, the avoidance only works if the diagnosis is
      suspected before the prescription is written, which is what makes the
      testing question in the discussions a clinical rather than an academic one.
    therapeutic_modality: OTHER
    treatment_term:
      preferred_term: Supportive Care
      term:
        id: NCIT:C15747
        label: Supportive Care
    target_mechanisms:
      - target: Valproate-Precipitated Fulminant Hepatic Failure
        treatment_effect: INHIBITS
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate
          liver failure
        explanation: >-
          The direct basis for the avoidance, and for its being unconditional on
          disease stage.
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Agents/circumstances to avoid: Valproic acid (Depakene®) and sodium
          divalproate (divalproex) (Depakote®) because of the risk of
          precipitating and/or accelerating liver disease.
        explanation: >-
          The GeneReviews agents-to-avoid statement, which names both the drug
          and its salt form and gives the reason. This is the formal management
          recommendation behind this record, and it says accelerating as well as
          precipitating, which covers the patient who already has liver disease
          when the drug is considered.
  - name: Liver Enzyme Surveillance
    description: >-
      Because the hepatic arm can move fast and can be triggered by a new
      medication, monitoring is scheduled rather than reactive. Liver enzymes are
      followed every three months or as clinically indicated, and liver function
      is rechecked specifically after any new antiseizure medication is
      introduced. That last clause is the one that matters most here: it converts
      the general valproate warning into a standing check on every subsequent
      drug decision, in a disease where seizure control keeps forcing new drug
      decisions.
    therapeutic_modality: OTHER
    treatment_term:
      preferred_term: Supportive Care
      term:
        id: NCIT:C15747
        label: Supportive Care
    target_mechanisms:
      - target: Hepatocellular Dysfunction and Failure
        treatment_effect: MODULATES
    evidence:
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          monitoring of liver enzymes every three months or as clinically
          indicated; monitoring of epilepsy with repeat liver function tests
          after introduction of any new anti-seizure medication.
        explanation: >-
          Gives both the routine interval and the event-triggered recheck after
          any new antiseizure medication, which is the specific surveillance
          behaviour this record asserts.
  - name: POLG Genotyping Before Valproate Exposure
    description: >-
      Genetic testing used as a preventive intervention rather than only as a
      diagnostic one. Sequencing POLG before starting valproate in a child with
      intractable seizures identifies those in whom the drug is dangerous, and the
      same logic extends beyond this syndrome: heterozygous POLG variation carries
      a substantially increased risk of valproate liver injury, with a reported
      odds ratio of 23.6, even in people who do not have the disease.
    therapeutic_modality: OTHER
    treatment_term:
      preferred_term: Genetic Testing
      term:
        id: NCIT:C15709
        label: Genetic Testing
    target_mechanisms:
      - target: Valproate-Precipitated Fulminant Hepatic Failure
        treatment_effect: INHIBITS
    evidence:
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          prospective genetic testing of POLG will identify individuals at high
          risk of this potentially fatal consequence of treatment
        explanation: >-
          States the preventive value of prospective genotyping in the authors'
          own terms.
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Heterozygous genetic variation in POLG was strongly associated with
          VPA-induced liver toxicity
        explanation: >-
          Establishes that the risk extends to heterozygous carriers, which is the
          basis for extending testing beyond suspected Alpers-Huttenlocher
          syndrome. The reported odds ratio of 23.6 appears in the same sentence
          of the source, inside a parenthetical that is omitted from the quote.
  - name: Non-Valproate Antiseizure Therapy and Supportive Care
    description: >-
      Seizure control is attempted with agents other than valproate, alongside
      supportive management of the hepatic and neurological disease. Control is
      characteristically poor, which is what the word intractable in the phenotype
      is doing, and no therapy modifies the underlying replication defect.
    therapeutic_modality: OTHER
    treatment_term:
      preferred_term: Supportive Care
      term:
        id: NCIT:C15747
        label: Supportive Care
    target_mechanisms:
      - target: Intractable Focal Epilepsy and Epilepsia Partialis Continua
        treatment_effect: MODULATES
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          All were given VPA due to intractable partial seizures.
        explanation: >-
          Establishes that the seizures are intractable, which is what
          necessitates alternative agents. Marked PARTIAL because the source
          documents the intractability and the valproate exposure rather than the
          efficacy of alternatives.
diagnosis:
  - name: POLG Sequencing
    description: >-
      Molecular diagnosis by sequencing POLG. In this disease the test is
      time-critical in an unusual way: its value is greatest before treatment
      rather than after, because a result that arrives after valproate has been
      started may arrive after the damage.
    diagnosis_term:
      preferred_term: Genetic Testing
      term:
        id: NCIT:C15709
        label: Genetic Testing
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Molecular studies revealed homozygous p.R597W or p.A467T mutations in
          two patients. The other two patients showed compound heterozygous
          mutations, p.A467T/p.Q68X and p.L83P/p.G888S.
        explanation: >-
          Demonstrates sequencing as the diagnostic modality and the biallelic
          results it yields.
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Establishing the diagnosis of a POLG-related disorder relies on
          clinical findings and the identification of biallelic POLG pathogenic
          variants on molecular genetic testing
        explanation: >-
          The GeneReviews diagnostic statement. It is worth noting that the
          diagnosis is defined as clinical findings plus biallelic variants
          together, not by genotype alone, which is why this entry keeps the
          electroclinical and hepatic features as part of the diagnostic picture
          rather than treating sequencing as sufficient on its own.
  - name: Electroencephalography
    description: >-
      Recording is used both to characterize the seizures and as a diagnostic
      clue, since early predominance of epileptiform discharges over the occipital
      region is common in POLG-related epilepsy. The findings vary between
      patients and between stages, so the occipital pattern supports the diagnosis
      when present but does not exclude it when absent.
    diagnosis_term:
      preferred_term: Electroencephalography
      term:
        id: NCIT:C38054
        label: Electroencephalography
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          early predominance of epileptiform discharges over the occipital region
          is common in POLG-induced epilepsy
        explanation: >-
          The diagnostic clue this record describes.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          the EEG and MRI findings varying between patients and stages of the
          disease
        explanation: >-
          The caveat that limits the sensitivity of the finding, which is why the
          description says it supports but does not exclude.
differential_diagnoses:
  - name: MELAS Syndrome
    disease_term:
      preferred_term: MELAS syndrome
      term:
        id: MONDO:0010789
        label: MELAS syndrome
    description: >-
      The other mitochondrial disease that presents with seizures and posterior
      cortical involvement in a child, and which shares the occipital emphasis
      seen here. The distinction is mechanistic and inheritance-based: MELAS
      arises from a maternally inherited mitochondrial DNA point mutation, this
      syndrome from biallelic nuclear POLG variants causing depletion of the
      mitochondrial genome.
    distinguishing_features:
      - Maternally inherited mitochondrial DNA point mutation rather than autosomal recessive nuclear POLG variants.
      - Stroke-like episodes crossing vascular territories rather than epilepsia partialis continua.
      - Lactic acidosis and ragged-red fibres on muscle biopsy are characteristic.
      - Hepatic failure is not a defining feature.
    evidence:
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          POLG-related disorders comprise a continuum of overlapping phenotypes
          that were clinically defined before the molecular basis was known.
        explanation: >-
          Supports that molecular definition is what separates these clinically
          overlapping mitochondrial presentations. Marked PARTIAL because the
          source addresses the POLG spectrum rather than comparing it with MELAS
          directly.
  - name: Rasmussen Subacute Encephalitis
    disease_term:
      preferred_term: Rasmussen subacute encephalitis
      term:
        id: MONDO:0016019
        label: Rasmussen subacute encephalitis
    description: >-
      The main non-metabolic cause of epilepsia partialis continua with cognitive
      decline in a child, and therefore the differential that matters at the
      bedside when a child presents with continuous focal seizures and is losing
      skills.
    distinguishing_features:
      - Unilateral hemispheric involvement with progressive hemiatrophy rather than a bilateral metabolic process.
      - Inflammatory histopathology with T-cell infiltrates and microglial nodules.
      - No hepatic involvement.
      - Immunotherapy and hemispherectomy are the treatment framework rather than avoidance of a hepatotoxic drug.
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          POLG gene testing should be considered in any child or adolescent who
          presents or develops intractable seizures with or without status
          epilepticus or epilepsia partialis
        explanation: >-
          The recommendation is framed around exactly the presentation this
          differential shares, which is why POLG testing is proposed for the whole
          presenting syndrome rather than only for suspected cases.
  - name: Non-POLG Mitochondrial DNA Depletion Syndromes
    description: >-
      Hepatocerebral mitochondrial DNA depletion can also arise from variants in
      DGUOK, MPV17 and TWNK among others, producing a similar combination of
      liver and brain disease. Separation is by gene. No MONDO disease_term is
      bound because this names a group of separate entities rather than one.
    distinguishing_features:
      - Causative variants in a gene other than POLG.
      - Seizure phenotype is generally less prominent than in POLG disease, with liver disease often dominating.
      - Epilepsia partialis continua and the occipital electrographic predominance are not characteristic.
    evidence:
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          POLG-related disorders can therefore be considered an overlapping
          spectrum of disease presenting from early childhood to late adulthood.
        explanation: >-
          Establishes the POLG-defined boundary of the spectrum this entry sits
          in. Marked PARTIAL because the source does not enumerate the other
          depletion-syndrome genes.
  - name: Juvenile and Adult POLG-Related Disorders
    description: >-
      The later-onset phenotypes caused by the same gene, including the
      ataxia-neuropathy spectrum, MEMSA, and progressive external
      ophthalmoplegia. These are not really a differential so much as the rest of
      the continuum this entry has carved a segment out of, and they are listed so
      the boundary is explicit. No MONDO disease_term is bound because several
      distinct entities are grouped here.
    distinguishing_features:
      - Onset after age 12 rather than in early childhood.
      - Peripheral neuropathy, ataxia and progressive external ophthalmoplegia dominate rather than the hepatocerebral triad.
      - Better prognosis than the early-onset group.
      - Hepatic failure is not a defining feature, though valproate sensitivity still applies.
    evidence:
      - reference: PMID:20301791
        reference_title: POLG-Related Disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Juvenile/adult-onset form (age 12-40 years: Disease is typically
          characterized by peripheral neuropathy, ataxia, seizures, stroke-like
          episodes, and, in individuals with longer survival, progressive external
          ophthalmoplegia (PEO). This group generally has a better prognosis than
          the early-onset group.
        explanation: >-
          Describes the juvenile and adult phenotypes and their better prognosis,
          which is the boundary this entry's scope note draws.
discussions:
  - discussion_id: ahs_valproate_toxicity_mechanism
    kind: CONTROVERSY
    status: UNDER_DISCUSSION
    prompt: >-
      If valproate hepatotoxicity in POLG disease is not mediated through
      mitochondrial DNA depletion, mutation, or impaired fatty acid metabolism,
      what does mediate it, and is impaired liver regeneration sufficient to
      explain a fatal outcome?
    attaches_to:
      - "pathophysiology#Valproate-Precipitated Fulminant Hepatic Failure"
    rationale: >-
      The intuitive account of this toxicity is almost irresistible: the disease
      is a mitochondrial DNA depletion syndrome, valproate has known mitochondrial
      effects, so valproate must be making the depletion worse. That account was
      tested and it failed. Toxicity was found not to be mediated through
      mitochondrial DNA depletion, not through mutation, and not through a defect
      of fatty acid metabolism, which removes all three of the obvious routes at
      once. What was found instead was that valproate inhibits human cellular
      proliferation at therapeutic doses and causes non-apoptotic cell death at
      high ones, and the authors read this as implicating impaired liver
      regeneration. That is a coherent story but it leaves real gaps. It does not
      explain the tissue specificity, since valproate reaches many proliferating
      tissues and the liver is the one that fails. It does not obviously explain
      the two-to-three-month latency, which is long for a direct antiproliferative
      effect and might instead reflect the time taken to exhaust a regenerative
      reserve. And it sits awkwardly with the strength of the genetic association,
      an odds ratio above twenty for heterozygous variation, since a mechanism
      that is independent of the mitochondrial genome ought to explain why POLG
      genotype matters so much. Resolving this is not merely mechanistic
      housekeeping: if the mediator were identified, it might be possible to make
      valproate safe rather than merely to avoid it.
    proposed_experiments:
      - experiment_id: ahs_regeneration_challenge_model
        name: Regenerative challenge in a POLG-variant hepatocyte model
        description: >-
          Partial-hepatectomy-style regenerative challenge, or its in-vitro
          equivalent using proliferation after controlled injury, in hepatocyte
          models carrying the recurrent POLG variants against isogenic controls,
          with and without valproate at therapeutic concentrations, measuring
          regenerative capacity rather than baseline viability.
        decision_criterion: >-
          A selective failure of regeneration in POLG-variant cells under
          valproate, with preserved baseline viability, would confirm impaired
          regeneration as the mediator. Equivalent regenerative failure regardless
          of POLG genotype would indicate the genotype acts through something
          else.
      - experiment_id: ahs_tissue_specificity_comparison
        name: Comparison of valproate antiproliferative effect across tissue lineages
        description: >-
          Parallel measurement of valproate's antiproliferative effect in
          hepatocyte, intestinal epithelial and haematopoietic progenitor models
          carrying the same POLG variants, testing whether the liver is uniquely
          sensitive or merely uniquely exposed.
        decision_criterion: >-
          Selective hepatocyte sensitivity would support a liver-specific
          mechanism and direct the search there. Comparable sensitivity across
          lineages would indicate the clinical liver specificity comes from
          exposure, first-pass concentration, or regenerative demand rather than
          from cellular susceptibility.
      - experiment_id: ahs_latency_reserve_modelling
        name: Testing whether latency reflects exhaustion of regenerative reserve
        description: >-
          Serial measurement of hepatic regenerative and functional markers from
          the start of valproate exposure in children with known POLG variants who
          require the drug's continuation for compelling reasons, or in a suitable
          animal model, to determine whether the two-to-three-month interval
          corresponds to a progressive decline or to an abrupt threshold event.
        decision_criterion: >-
          A progressive measurable decline preceding failure would support
          reserve exhaustion and would identify a monitoring window. An abrupt
          transition without antecedent change would argue against the reserve
          model and against the feasibility of monitoring.
    evidence:
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: REFUTE
        evidence_source: IN_VITRO
        snippet: >-
          Therapeutic doses of VPA inhibited human cellular proliferation and high
          doses caused nonapoptotic cell death, which was not mediated through
          mitochondrial DNA depletion, mutation, or a defect of fatty acid
          metabolism.
        explanation: >-
          The negative result that creates the controversy, excluding all three
          intuitive mechanisms in a single experiment.
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          These findings implicate impaired liver regeneration in VPA toxicity
        explanation: >-
          The positive hypothesis put in place of the refuted ones, which the
          proposed experiments are designed to test directly.
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Heterozygous genetic variation in POLG was strongly associated with
          VPA-induced liver toxicity
        explanation: >-
          The strength of the genotype effect, reported in the same sentence as an
          odds ratio of 23.6, is what a non-mitochondrial mechanism has to account
          for, and is the tension this discussion identifies.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The time from VPA exposure to liver failure was between 2 and 3 months.
          Liver failure was reversible in one patient.
        explanation: >-
          The latency the mechanism must explain, and the single reversible case
          that suggests the process is not instantaneously irreversible.
  - discussion_id: ahs_polg_testing_threshold
    kind: OPEN_QUESTION
    status: OPEN
    prompt: >-
      Which children with intractable seizures should have POLG sequenced before
      valproate is started, and can a test that takes days be made to govern a
      decision that is often made in hours?
    attaches_to:
      - "pathophysiology#Valproate-Precipitated Fulminant Hepatic Failure"
    rationale: >-
      The proposal in the literature is broad: consider POLG testing in any child
      or adolescent who presents with or develops intractable seizures, with or
      without status epilepticus or epilepsia partialis continua. That is
      described as an emerging standard of care rather than an established one,
      and the gap between those two phrases is where the real question lives.
      Arguments for the broad threshold are strong. The consequence of missing the
      diagnosis is a preventable death, POLG variants occur in every ancestry
      group so no population can be excluded, and the risk extends beyond the
      syndrome itself because heterozygous variation alone carries a substantially
      elevated risk. Arguments against a universal rule are practical rather than
      principled. Intractable seizures are common and this disease is rare, so a
      broad rule tests very many children to find few; sequencing turnaround is
      usually days while the decision to start valproate is often made the same
      day; and variants of uncertain significance in a large gene will generate
      results that are themselves hard to act on. What is genuinely unresolved is
      not whether testing helps but what the operating policy should be, and no
      study has compared candidate thresholds against outcomes.
    proposed_experiments:
      - experiment_id: ahs_testing_yield_by_threshold
        name: Diagnostic yield and outcome by testing threshold
        description: >-
          Retrospective and then prospective evaluation across paediatric epilepsy
          centres of several candidate testing thresholds, from the broadest (all
          intractable seizures) to narrower ones (epilepsia partialis continua,
          occipital electrographic predominance, regression, or any combination),
          measuring diagnostic yield, number needed to test, and cases of
          valproate hepatotoxicity averted.
        decision_criterion: >-
          A threshold that captures nearly all cases at an acceptable number
          needed to test would justify a specific policy recommendation. If yield
          falls steeply as soon as the threshold is narrowed at all, that argues
          for the broad rule despite its cost.
      - experiment_id: ahs_rapid_targeted_genotyping
        name: Rapid targeted genotyping of recurrent variants as a pre-prescription test
        description: >-
          Development and evaluation of a same-day targeted assay for the
          recurrent POLG variants, including p.A467T, p.R597W and p.Q1236H,
          deployed as a pre-prescription check rather than as a diagnostic test,
          with sensitivity measured against full sequencing.
        decision_criterion: >-
          If a rapid targeted panel captures a large majority of clinically
          relevant genotypes, it can govern the prescribing decision in real time
          while full sequencing proceeds. Low sensitivity would mean the panel
          gives false reassurance and should not be used this way.
      - experiment_id: ahs_alternative_first_line_policy
        name: Outcome of a policy of avoiding valproate first-line in intractable childhood seizures
        description: >-
          Comparison of centres that avoid valproate as a first-line agent in
          undiagnosed intractable childhood seizures against those that do not,
          measuring both hepatotoxicity events and any cost in seizure control
          from the deferred use of an effective drug.
        decision_criterion: >-
          If avoidance prevents hepatotoxicity at little cost in seizure control,
          policy can sidestep the testing-turnaround problem entirely. A
          meaningful loss of seizure control would mean testing, not avoidance, is
          the right instrument.
    evidence:
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Our data support an emerging proposal that POLG gene testing should be
          considered in any child or adolescent who presents or develops
          intractable seizures with or without status epilepticus or epilepsia
          partialis
        explanation: >-
          The broad threshold under discussion, stated by its proponents as an
          emerging proposal rather than as settled practice.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          POLG mutations have been observed in every ethnic group studied to
          date
        explanation: >-
          Removes ancestry as a legitimate basis for narrowing the testing
          threshold.
      - reference: PMID:21038416
        reference_title: >-
          Polymerase gamma gene POLG determines the risk of sodium
          valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          prospective genetic testing of POLG will identify individuals at high
          risk of this potentially fatal consequence of treatment
        explanation: >-
          Supports prospective testing and, by covering heterozygotes without the
          syndrome, widens the population for whom testing has value beyond
          suspected Alpers-Huttenlocher syndrome.
  - discussion_id: ahs_occipital_predominance
    kind: KNOWLEDGE_GAP
    status: OPEN
    prompt: >-
      Post-mortem work shows the respiratory chain deficiency falls
      preferentially on inhibitory interneurons of the occipital cortex, but why
      those cells and why that lobe, when every neuron carries the same POLG
      genotype? And does occipital cortex have a general vulnerability that
      mechanistically unrelated epilepsies all expose?
    attaches_to:
      - "pathophysiology#Selective Interneuron and Pyramidal Neuron Loss in Occipital Cortex"
    rationale: >-
      This gap has moved rather than closed, and it is worth being precise about
      what part of it the evidence now answers. A systemic defect in replicating
      the mitochondrial genome should not have a lobe preference, yet the
      epileptiform activity of this disease has one. Quantitative neuropathology
      supplies the missing middle term: the deficiency is not uniform across
      cortex but concentrated in inhibitory interneurons and pyramidal neurons of
      occipital cortex and in Purkinje cells, and those populations are depleted.
      So the chain from a genome-maintenance defect to occipital seizures now has
      a cellular link in it, and the entry models that link rather than leaving a
      hole.

      What remains open is the selectivity itself, at two levels. Why
      interneurons: the usual explanation is that fast-spiking inhibitory cells
      carry the highest sustained metabolic load in cortex and so fail first under
      a shared energetic constraint, which is plausible and, in these sources,
      untested. Why occipital: nothing explains why the same cell class fails
      there rather than in frontal or temporal cortex, and the study did not
      compare regions within a brain in a way that would settle it. The authors
      themselves state their causal reading as a belief rather than a
      demonstration.

      There is also a caution against over-reading the regional claim. The
      electrographic and imaging findings vary between patients and between
      stages, which is not what a fixed metabolic gradient would produce.

      Finally, the company this observation keeps still matters. This knowledge
      base contains two other occipital-onset epilepsies, childhood occipital
      visual epilepsy and photosensitive occipital lobe epilepsy, which share no
      etiology with this disease or with each other beyond the location. The
      interneuron finding makes that convergence more interesting rather than
      less: if occipital inhibitory circuitry has a general fragility, a
      bioenergetic disease and two idiopathic epilepsies could be exposing the
      same weak point by different routes. No single-disease study can test that.
    proposed_experiments:
      - experiment_id: ahs_interneuron_metabolic_load
        name: Testing whether interneuron selectivity follows metabolic load
        description: >-
          Within the same post-mortem brains, comparison of respiratory chain
          subunit deficiency between fast-spiking parvalbumin-positive
          interneurons and lower-firing interneuron subtypes, against a measure of
          each population's baseline metabolic demand. This asks directly whether
          the vulnerable population is the one with the highest sustained energy
          requirement, which is the standard explanation and has not been tested
          here.
        decision_criterion: >-
          Deficiency tracking firing rate and metabolic demand across interneuron
          subtypes would establish energetic load as the selectivity mechanism.
          Uniform deficiency across subtypes, or selectivity that does not follow
          demand, would mean something other than metabolic load picks the
          vulnerable cells.
      - experiment_id: ahs_regional_mtdna_quantification
        name: Regional quantification of mitochondrial DNA depletion in post-mortem brain
        description: >-
          Quantification of mitochondrial DNA copy number and respiratory chain
          subunit expression across cortical regions in post-mortem tissue from
          patients with POLG disease, testing directly whether occipital cortex is
          more depleted or more functionally compromised than frontal and temporal
          cortex in the same brain.
        decision_criterion: >-
          Greater occipital depletion within the same brain would support a
          regional metabolic vulnerability. Uniform depletion across regions would
          mean the electrographic predominance arises from network properties
          rather than from where the molecular lesion bites hardest.
      - experiment_id: ahs_cross_mitochondrial_disease_eeg_survey
        name: Occipital predominance across mitochondrial diseases
        description: >-
          Systematic review of interictal electroencephalographic localization
          across mitochondrial diseases with differing molecular lesions, testing
          whether occipital predominance tracks mitochondrial dysfunction in
          general or is specific to POLG.
        decision_criterion: >-
          A shared occipital predominance across mitochondrial diseases would
          support a general energetic vulnerability of occipital cortex.
          Specificity to POLG would point to something about this lesion in
          particular.
      - experiment_id: ahs_cross_etiology_occipital_comparison
        name: Cross-etiology comparison of occipital epileptogenicity
        description: >-
          Comparison of occipital cortical excitability measures, such as the
          visual evoked response amplitude and after-discharge parameters already
          used in photosensitive occipital lobe epilepsy, across patients with
          POLG disease, the self-limited occipital epilepsies of childhood, and
          controls, to test whether a shared occipital excitability trait exists
          independent of etiology.
        decision_criterion: >-
          A shared excitability abnormality across etiologically unrelated
          occipital epilepsies would establish a general vulnerability worth
          modelling as such. Divergent physiology would mean the convergence on
          one lobe is coincidental and each disease reaches it by its own route.
    evidence:
      - reference: PMID:30021052
        reference_title: >-
          Dissecting the neuronal vulnerability underpinning Alpers' syndrome: a
          clinical and neuropathological study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Quantitative immunofluorescence showed severe respiratory chain
          deficiencies involving mitochondrial respiratory chain subunits of
          complex I and, to a lesser extent, complex IV in inhibitory interneurons
          and pyramidal neurons in the occipital cortex and in Purkinje cells of
          the cerebellum. Diminished densities of these neuronal populations were
          also observed.
        explanation: >-
          The evidence that moved this gap rather than closing it. It establishes
          the cellular selectivity and its occipital location, which is the part
          of the question that is now answered, and says nothing about why those
          cells or that lobe, which is the part that remains open.
      - reference: PMID:30021052
        reference_title: >-
          Dissecting the neuronal vulnerability underpinning Alpers' syndrome: a
          clinical and neuropathological study.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Since our understanding of the mechanisms contributing the neurological
          features in Alpers' syndrome is rudimentary, we performed a detailed and
          quantitative neuropathological study on 13 patients with clinically and
          histologically-defined Alpers' syndrome with ages ranging from 2 months
          to 18 years.
        explanation: >-
          The authors' own characterization of mechanistic understanding in this
          disease as rudimentary, which is the state this gap records, together
          with the cohort size that bounds how much the study can settle.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          early predominance of epileptiform discharges over the occipital region
          is common in POLG-induced epilepsy
        explanation: >-
          The observation this gap is about, reported as common and useful enough
          to serve as a recognition feature.
      - reference: PMID:20138553
        reference_title: >-
          POLG DNA testing as an emerging standard of care before instituting
          valproic acid therapy for pediatric seizure disorders.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          the EEG and MRI findings varying between patients and stages of the
          disease
        explanation: >-
          The variability that a fixed regional-vulnerability explanation has to
          accommodate, and the reason the first proposed experiment measures
          depletion within individual brains rather than comparing across
          patients.

📚

References & Deep Research

References

3

PMID:20301791

POLG-Related Disorders.

No top-level findings curated for this source.

PMID:21038416

Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity.

No top-level findings curated for this source.

PMID:20138553

POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Alpers–Huttenlocher Syndrome: Disease-Characteristics Research Report

Edison Scientific Literature 35 citations 2026-08-05T20:58:28.862777

Alpers–Huttenlocher Syndrome: Disease-Characteristics Research Report

Scope. This report treats classic Alpers–Huttenlocher syndrome (AHS) as the severe childhood hepatocerebral end of the POLG-related-disorder spectrum. Evidence is labeled as human clinical, human pathology, in vitro, or preclinical. Exact PMID links are provided where recoverable from the retrieved evidence; DOI URLs are supplied for all major publications.

Executive summary

AHS is a rare, usually autosomal-recessive mitochondrial DNA (mtDNA)-maintenance disorder characterized by developmental regression, refractory epilepsy—often occipital and progressing to status epilepticus—and hepatopathy/liver failure. More than 90% of classic cases are attributed to biallelic pathogenic variants in POLG, encoding the catalytic subunit of mitochondrial DNA polymerase γ; rare Alpers-like phenotypes occur with other mtDNA-maintenance or mitochondrial translation genes. POLG dysfunction causes tissue-specific mtDNA depletion, respiratory-chain failure—especially complex I deficiency—and selective injury to cortical inhibitory interneurons, pyramidal neurons, cerebellar Purkinje cells, and hepatocytes. The disease is rapidly progressive and generally fatal in childhood. Valproate can precipitate catastrophic hepatic failure and is contraindicated. No approved disease-modifying treatment exists; management is multidisciplinary and mainly palliative. Recent 2024 work has clarified status-epilepticus burden and childhood clinical trajectories and established patient-derived cerebral organoids for therapeutic screening. (rahman2019polgrelateddisordersand pages 3-4, rahman2020mitochondrialdiseasein pages 5-6, hayhurst2019dissectingtheneuronal pages 1-4, rotig2024distinctclinicalcourses pages 1-2, hikmat2024statusepilepticusin pages 1-2)

Domain	Key finding/statistic	Evidence type	Source/year
Childhood clinical course	Retrospective monocentric cohort of 40 children with childhood-onset POLG deficiency identified 3 clinical patterns: neurologic, hepatic, and gastrointestinal; 24/40 (60%) required urgent neurointensive care for seizures/status epilepticus; only 6/40 survived; hepatic presentations had earliest onset and shortest survival; valproate was highlighted as an avoidable precipitant of hepatic failure/death (rotig2024distinctclinicalcourses pages 1-2)	Human clinical cohort	Rötig et al., 2024
Status epilepticus burden	Multinational study of 195 genetically confirmed POLG patients: 67% (130/194) had epilepsy; 77% (97/126) with epilepsy developed status epilepticus; median SE onset 7 years; 97% (91/94) convulsive SE; 67% (56/84) epilepsia partialis continua; 66% (57/86) refractory/super-refractory SE; median time from SE onset to death 5 months (hikmat2024statusepilepticusin pages 1-2)	Human multinational cohort	Hikmat et al., 2024
Pediatric natural history	Early-onset POLG pediatric cohort of 27 patients; for Alpers phenotype (n=19), 100% had seizures and liver dysfunction; overall cohort mortality 85% (22/26); median age at death 15.8 months; median survival from onset 4.9 months; liver failure was main cause of death (13/22) (hikmat2017theclinicalspectrum pages 6-7)	Human clinical natural-history cohort	Hikmat et al., 2017
Core syndrome definition	AHS is a severe pediatric POLG disorder characterized by the triad of developmental regression, intractable seizures, and liver failure; about 70% of childhood POLG presentations are reported as AHS (rahman2019polgrelateddisordersand pages 3-4, rahman2020mitochondrialdiseasein pages 5-6)	Human clinical review synthesizing cohorts	Rahman & Copeland, 2019
EEG/MRI phenotype	POLG-related Alpers disease shows occipital-predominant epileptiform abnormalities; in one pediatric cohort, MRI lesions were present in 82% at onset and 88% during disease course; EEG often showed high-voltage polyspike-slow waves in occipitotemporal regions (hikmat2017theclinicalspectrum pages 4-6)	Human clinical cohort	Hikmat et al., 2017
Neuropathology	Post-mortem study of 13 clinically/histologically defined Alpers patients found severe respiratory-chain deficiency, especially complex I, in inhibitory interneurons, pyramidal neurons of occipital cortex, and Purkinje cells, with reduced neuronal densities supporting selective neuronal vulnerability underlying seizures/ataxia (hayhurst2019dissectingtheneuronal pages 1-4, hayhurst2019dissectingtheneuronal pages 13-15, hayhurst2019dissectingtheneuronal pages 10-13)	Human neuropathology	Hayhurst et al., 2019
Common POLG variants	Frequently reported epilepsy-associated POLG variants include p.Ala467Thr (A467T), p.Trp748Ser (W748S), and p.Gly848Ser (G848S); mtDNA depletion is a key downstream defect in severe disease (anagnostou2016epilepsydueto pages 11-12, saneto2013alpershuttenlochersyndrome. pages 1-2)	Human genetic/clinical review	Anagnostou et al., 2016; Saneto et al., 2013
Liver pathology/biomarkers	Characteristic liver pathology includes microvesicular steatosis, bile duct proliferation, hepatocellular necrosis, bridging fibrosis/cirrhosis; reported biomarkers include elevated FGF21, lactate, and plasma alanine in POLG disease (rahman2019polgrelateddisordersand pages 8-10)	Human pathology/review	Rahman & Copeland, 2019
Experimental therapy: NAD+ precursor	Patient-derived iPSC cortical organoids from Alpers disease with POLG A467T/P589L recapitulated neuronal loss, mtDNA depletion, and complex I defects; nicotinamide riboside improved neuronal markers and normalized mitochondrial/synaptic transcriptomic pathways toward control profiles (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)	In vitro patient-derived organoid study	Hong et al., 2024

Table: This compact table summarizes high-yield evidence for Alpers-Huttenlocher syndrome across natural history, neuropathology, genetics, and emerging experimental therapeutics. It emphasizes the most clinically actionable 2017-2024 findings with clear evidence-type labeling.

1. Disease information

Definition and classification

AHS is an early-onset, progressive mitochondrial hepatocerebral encephalopathy/mtDNA depletion syndrome. The classic triad is progressive neurodevelopmental regression, intractable seizures, and liver disease. Typical onset is between approximately 6 months and 3 years, often after apparently normal early development, although congenital/infantile and juvenile or rare adult-onset POLG phenotypes occur. Later presentations are often dominated by epileptic encephalopathy and ataxia rather than the complete early-childhood triad. (rahman2019polgrelateddisordersand pages 3-4, rahman2020mitochondrialdiseasein pages 5-6, hayhurst2019dissectingtheneuronal pages 1-4)

Direct abstract quote (human neuropathology, published October 2019): “Alpers’ syndrome is characterized by intractable epilepsy, developmental regression and liver failure which typically affects children aged 6 months–3 years.” The same abstract describes the disorder as progressive, incurable, and ultimately fatal from drug-resistant status epilepticus, frequently with liver failure. (hayhurst2019dissectingtheneuronal pages 1-4)

Identifiers and synonyms

Orphanet: ORPHA:726, Alpers syndrome, supported by the Open Targets disease record. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)
MONDO: the closely mapped entity MONDO:0008758, mitochondrial DNA depletion syndrome 4A (Alpers type), is linked to POLG in Open Targets. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)
OMIM: commonly represented as 203700, Mitochondrial DNA depletion syndrome 4A (Alpers type); causal gene POLG, OMIM 174763. This identifier should be independently validated during database ingestion because OMIM itself was not directly retrieved.
MeSH: “Alpers Syndrome.”
ICD-10/ICD-11: no uniquely specific, universally used AHS code was confirmed. Cases are generally coded under mitochondrial metabolism disorders/other specified metabolic or neurologic disease; coding depends on jurisdiction.
Synonyms: Alpers syndrome; Alpers disease; Alpers–Huttenlocher disease; progressive neuronal degeneration of childhood with liver disease; POLG-related Alpers syndrome; mitochondrial DNA depletion syndrome 4A/MTDPS4A.

The evidence is predominantly aggregated disease-level evidence from cohorts, reviews, pathology series, and registries. It is not derived from routine individual-patient EHR extraction, although retrospective cohorts abstracted individual clinical records. (NCT03034512 chunk 1, rotig2024distinctclinicalcourses pages 1-2, hikmat2024statusepilepticusin pages 1-2)

2. Etiology and risk/protective factors

Causal factors

Classic AHS is chiefly caused by biallelic germline pathogenic or likely pathogenic POLG variants. Inheritance is autosomal recessive. POLG encodes the catalytic subunit of the mitochondrial replicase responsible for mtDNA replication and base-excision repair. Impaired polymerase/exonuclease function produces mtDNA depletion and sometimes multiple mtDNA deletions, followed by oxidative-phosphorylation failure. (pronicka2011drugresistantepilepsiaand pages 6-7, hayhurst2019dissectingtheneuronal pages 1-4, saneto2013alpershuttenlochersyndrome. pages 1-2)

Rare Alpers-like phenotypes have been associated with TWNK, FARS2, NARS2, and PARS2. These should be distinguished from molecularly confirmed POLG-AHS in a knowledge base. (hikmat2017theclinicalspectrum pages 6-7, rahman2020mitochondrialdiseasein pages 5-6)

Genetic risk and modifiers

Common POLG variants among epilepsy-spectrum cases include p.Ala467Thr (A467T), p.Trp748Ser (W748S), and p.Gly848Ser (G848S). These variants are not AHS-specific: the same genotype can produce markedly different POLG-spectrum phenotypes. Homozygous linker-region variants may have better outcomes than some compound-heterozygous combinations, but recent childhood data did not identify a reliable genotype–clinical-course correlation. Nuclear modifiers, mtDNA background, and physiologic stress are plausible contributors but are not validated prognostic tests. (anagnostou2016epilepsydueto pages 11-12, rotig2024distinctclinicalcourses pages 1-2)

No established susceptibility locus beyond causal POLG alleles, validated protective POLG allele, or reproducible epigenetic modifier has entered clinical use. Pathogenic alleles are expected to be individually rare in population databases; variant-specific gnomAD frequencies and ClinVar ACMG classifications must be captured per transcript and genome build rather than assigning a disease-wide frequency.

Environmental and gene–environment interactions

AHS is not caused by lifestyle, toxin, occupational exposure, or infection. The most important interaction is POLG deficiency × valproate exposure, which can precipitate rapidly progressive or fulminant hepatic failure and avoidable death. Viral-like prodromes, fever, fasting/catabolism, or intercurrent illness are sometimes temporally associated with neurologic deterioration, but they are triggers of decompensation rather than primary causes. (rahman2019polgrelateddisordersand pages 3-4, pronicka2011drugresistantepilepsiaand pages 6-7, rotig2024distinctclinicalcourses pages 1-2)

No diet, exercise regimen, environmental exposure, or infection has been shown to prevent AHS in genetically affected children. Avoidance of valproate and catabolic stress is protective against preventable deterioration, not against the underlying genetic disease.

3. Phenotypes

Phenotype	Type/course and approximate frequency	Suggested HPO term
Developmental regression/progressive encephalopathy	Core feature; often follows initially normal development; severe, progressive	HP:0002376 Developmental regression; HP:0001298 Encephalopathy
Global developmental delay	100% in one early-onset POLG cohort; variable before explosive seizure onset	HP:0001263 Global developmental delay
Epilepsy	Usually focal/occipital initially; mixed seizure types become drug-resistant; 89% in one pediatric cohort and 67% across a broader 2024 POLG cohort	HP:0001250 Seizure; HP:0007359 Focal-onset seizure
Status epilepticus/EPC	Episodic then recurrent/prolonged; frequently refractory or super-refractory	HP:0002133 Status epilepticus; HP:0011172 Epilepsia partialis continua
Hepatic dysfunction/failure	Progressive or abrupt, especially after valproate; may be absent early	HP:0001410 Decreased liver function; HP:0001399 Hepatic failure
Hypotonia	96% in one early-onset cohort; progressive	HP:0001252 Hypotonia
Failure to thrive/faltering growth	89% in one pediatric cohort	HP:0001508 Failure to thrive
Ataxia	Common in later/juvenile disease; 69% among POLG patients with SE in 2024 cohort	HP:0001251 Ataxia
Stroke-like episodes	Associated with seizure-associated cortical lesions; 57% among patients with SE	HP:0002401 Stroke-like episode
Visual impairment/cortical blindness	Related to occipital cortical disease; variable	HP:0100704 Cortical visual impairment; HP:0000510 Rod-cone dystrophy only if documented
Peripheral neuropathy	More prominent in broader POLG spectrum; may mimic inflammatory polyradiculoneuropathy	HP:0009830 Peripheral neuropathy
Vomiting/gastroparesis/pseudo-obstruction	Neurogastrointestinal POLG course, often later and longer-lived than classic hepatic AHS	HP:0002013, HP:0002578, HP:0004389
Lactic acidemia/elevated alanine	Variable supportive laboratory abnormalities; normal values do not exclude disease	HP:0003128 Lactic acidosis; HP:0003348 Hyperalaninemia
Hypertransaminasemia/hypoalbuminemia/coagulopathy	Progressive hepatic laboratory abnormalities	HP:0002910, HP:0003073, HP:0003256

In the 2017 cohort, global developmental delay, hypotonia, and faltering growth occurred in 100%, 96%, and 89%, respectively. Epilepsy occurred in 89%; liver failure was a major determinant of death. (hikmat2017theclinicalspectrum pages 1-2, hikmat2017theclinicalspectrum pages 6-7)

The 2024 multinational POLG study found epilepsy in 130/194 (67%). Among evaluable epileptic patients, 97/126 (77%) developed status epilepticus at a median age of 7 years; 97% had convulsive SE, 67% EPC, and 66% refractory/super-refractory SE. These figures encompass the broader POLG spectrum and should not be interpreted as AHS-only frequencies. (hikmat2024statusepilepticusin pages 1-2)

Quality of life: no validated AHS-specific EQ-5D, SF-36, or PROMIS series was identified. Functional impact is nevertheless profound: loss of developmental abilities, recurrent intensive-care admissions, feeding and respiratory dependence, severe visual/motor disability, and high caregiver burden. Formal patient-reported outcomes are a major evidence gap.

4. Genetic and molecular information

Causal gene

POLG — DNA polymerase gamma, catalytic subunit; Ensembl ENSG00000140521; autosomal nuclear gene. Open Targets shows strong disease association with Alpers syndrome and MTDPS4A based on genetic and literature evidence. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)
POLGARF appears computationally in Open Targets because it overlaps the POLG locus/alternative reading frame, but current clinical causality for classic AHS rests on POLG, not an independently established POLGARF mechanism. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)

Variant classes and consequences

Pathogenic variants include missense, nonsense, frameshift, splice-site, and small insertion/deletion alleles across the exonuclease, linker, and polymerase domains. They are constitutional/germline, usually compound heterozygous or homozygous—not somatic. Functional consequences are predominantly loss or severe impairment of polymerase fidelity/processivity, proofreading, DNA binding, or interaction with the accessory subunit, producing mtDNA copy-number loss and respiratory-chain dysfunction. (hikmat2017theclinicalspectrum pages 4-6, anagnostou2016epilepsydueto pages 11-12, saneto2013alpershuttenlochersyndrome. pages 1-2)

Frequently reported variants include:

NM_002693.3:c.1399G>A, p.(Ala467Thr) — linker-region missense; recurrent pathogenic allele.
c.2243G>C, p.(Trp748Ser) — recurrent missense, often occurring on a haplotype with p.Glu1143Gly; pathogenicity must be interpreted in phase.
c.2542G>A, p.(Gly848Ser) — recurrent polymerase-domain missense.
c.1766C>T, p.(Pro589Leu) — used with A467T in the 2024 Alpers organoid model. (anagnostou2016epilepsydueto pages 11-12, hong2024thenad+precursor pages 1-4)

A knowledge-base implementation should store ClinVar accession, review status, ACMG classification, phase, transcript, ancestry-specific gnomAD frequency, and functional evidence separately for every allele. No large chromosomal abnormality, repeat expansion, or acquired somatic mechanism is characteristic of AHS.

5. Environmental, lifestyle, and infectious information

No reproducible environmental, behavioral, infectious, radiation, smoking, alcohol, or occupational cause is known. Pediatric age is a feature of classic phenotypic expression rather than an exposure. Sex-linked risk is not expected because POLG is autosomal. Family history may be absent because parents are usually unaffected carriers.

Clinically relevant precipitating factors are valproate, intercurrent illness, fasting/catabolism, and sustained seizure activity. Their effects are superimposed on genetically reduced mitochondrial reserve. A viral prodrome has occasionally preceded seizure onset, but no specific pathogen or immune-mediated etiology is established. (rahman2019polgrelateddisordersand pages 3-4, rotig2024distinctclinicalcourses pages 1-2)

6. Mechanism and pathophysiology

Causal chain

Biallelic POLG dysfunction (upstream) → defective mtDNA replication/repair → tissue-specific mtDNA depletion and occasionally deletions → insufficient synthesis of mtDNA-encoded oxidative-phosphorylation subunits → respiratory-chain deficiency, especially complex I and less consistently complex IV → impaired ATP production, abnormal NADH/NAD+ metabolism, ROS excess, mitophagy/senescence and reduced energetic reserve → selective failure and death of high-energy neurons and hepatocytes → occipital epilepsy, status epilepticus, regression, ataxia, and hepatic failure. Seizures further increase energetic demand and can drive a feed-forward cycle of acute focal necrosis and stroke-like injury. (hayhurst2019dissectingtheneuronal pages 1-4, hayhurst2019dissectingtheneuronal pages 13-15, hayhurst2019dissectingtheneuronal pages 10-13, saneto2013alpershuttenlochersyndrome. pages 1-2)

Human pathology: examination of 13 postmortem brains showed severe complex I and lesser complex IV deficiencies in occipital-cortical GABAergic interneurons and pyramidal neurons and cerebellar Purkinje cells, with reduced neuronal densities. Loss of inhibitory neurons plausibly shifts excitation–inhibition balance toward seizures; Purkinje-cell loss contributes to ataxia. (hayhurst2019dissectingtheneuronal pages 1-4, hayhurst2019dissectingtheneuronal pages 13-15)

GO suggestions: mitochondrial DNA replication (GO:0006264); mitochondrial genome maintenance (GO:0000002); mitochondrial electron transport, NADH to ubiquinone (GO:0006120); oxidative phosphorylation (GO:0006119); ATP metabolic process (GO:0046034); cellular response to oxidative stress (GO:0034599); mitophagy (GO:0000423); neuron apoptotic process (GO:0051402).

Cell Ontology suggestions: neuron (CL:0000540), GABAergic neuron (CL:0000617), glutamatergic neuron (CL:0000679), cerebellar Purkinje cell (CL:0000121), astrocyte (CL:0000127), hepatocyte (CL:0000182).

Pathology and biochemical abnormalities

Brain pathology includes occipital-predominant cortical atrophy, spongiosis/microvacuolation, laminar neuronal loss, astrocytosis, and focal necrosis, with involvement of thalamus, basal ganglia, and cerebellum. Liver pathology includes microvesicular steatosis, bile-ductular proliferation, hepatocyte dropout/necrosis, architectural disorganization, bridging fibrosis, and cirrhosis. (rahman2019polgrelateddisordersand pages 8-10, hayhurst2019dissectingtheneuronal pages 13-15)

Supportive biochemical findings include elevated lactate, alanine, transaminases, bilirubin, ammonia, prolonged INR, low albumin, respiratory-chain enzyme defects, and tissue mtDNA depletion. FGF21 may be elevated but is not specific or independently diagnostic. Cerebral folate deficiency has been described. (rahman2019polgrelateddisordersand pages 8-10, hikmat2017theclinicalspectrum pages 4-6)

Molecular profiling and advanced technologies

In 2024, patient-derived A467T/P589L iPSC cortical organoids reproduced neuronal loss, mtDNA depletion, complex I loss, ROS excess, and NADH-pathway dysregulation. Transcriptomic profiling identified altered electron-transport, ATP-synthase, mitophagy, synaptic, and neuroinflammatory programs. Nicotinamide riboside shifted expression toward control profiles and improved mitochondrial and neuronal readouts; this is in-vitro proof of concept, not clinical efficacy. (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)

Another 2024 cerebral-organoid study reported neurodegeneration, mtDNA depletion, complex I deficiency, dysregulated neuronal-development pathways, and increased NOTCH/JAK–STAT signaling; metformin improved several mitochondrial and cell-death measures but did not rescue all vulnerable neuronal populations. Again, this remains preclinical and should not justify off-label treatment.

No validated AHS single-cell atlas, spatial-transcriptomic diagnostic signature, clinical proteomic panel, lipidomic biomarker, or CRISPR therapy was identified as of the requested 2023–2024 window.

7. Anatomical structures affected

Primary organs: brain and liver.
Brain regions: bilateral cerebral cortex with strong occipital/calcarine and parieto-occipital predilection; thalamus, basal ganglia, hippocampal regions, and cerebellar cortex may be involved. Lesions may be multifocal/asymmetric during stroke-like episodes but the disorder is systemic rather than a fixed unilateral disease. (hayhurst2019dissectingtheneuronal pages 1-4, rahman2019polgrelateddisordersand pages 8-10)
Peripheral/autonomic nervous system: peripheral nerves, nerve roots, enteric nervous system, and autonomic pathways can be affected in broader childhood POLG disease. (rotig2024distinctclinicalcourses pages 1-2)
Tissues/cells: cortical gray matter, inhibitory interneurons, pyramidal neurons, Purkinje cells, astroglia, hepatocytes and biliary/ductular compartments.
Subcellular compartment: mitochondrion (GO:0005739), mitochondrial nucleoid (GO:0042645), mitochondrial matrix (GO:0005759), respiratory-chain complex I (GO:0005747).

UBERON suggestions: brain (UBERON:0000955), cerebral cortex (UBERON:0000956), occipital lobe (UBERON:0002021), thalamus (UBERON:0001897), cerebellum (UBERON:0002037), liver (UBERON:0002107), peripheral nerve (UBERON:0001021).

8. Temporal development

Classic onset is pediatric, usually 6 months–3 years, and often insidious until explosive focal seizures or status epilepticus. Early stages may include hypotonia, developmental delay, poor growth, vomiting, or mild liver-test abnormalities. Intermediate disease includes recurrent focal/generalized seizures, EPC, regression, ataxia, visual loss, stroke-like lesions, and progressive hepatopathy. Advanced disease features refractory/super-refractory SE, severe encephalopathy, feeding and respiratory failure, coagulopathy, cirrhosis or acute liver failure, sepsis, and death. (rahman2019polgrelateddisordersand pages 3-4, rahman2020mitochondrialdiseasein pages 5-6, hikmat2024statusepilepticusin pages 1-2)

The course is progressive with stepwise declines after seizures or metabolic stress, not relapsing-remitting. Temporary seizure control is not neurologic remission. Critical intervention windows are before valproate exposure and early in escalating seizure activity, when prompt aggressive management may limit the seizure–energy-failure feedback loop.

9. Inheritance and population

Inheritance is autosomal recessive. For two confirmed heterozygous parents, each pregnancy carries a 25% probability of an affected child, 50% probability of an unaffected carrier, and 25% probability of inheriting neither familial allele. Penetrance of two severe pathogenic alleles appears high, but age at onset and expressivity vary substantially across the POLG spectrum. Anticipation is not expected. Germline mosaicism is not a recognized major mechanism, although standard residual-risk counseling applies.

Reliable AHS-specific incidence/prevalence estimates were not identified; Orphanet classifies it as rare. POLG-spectrum frequency estimates cannot be substituted for classic AHS. AHS reportedly represents about 70% of pediatric POLG presentations in a multinational context, but this is a referral-cohort proportion, not population prevalence. (rahman2019polgrelateddisordersand pages 3-4)

Founder or enriched POLG alleles include A467T and W748S in some European populations, but variant geography does not restrict disease to any ethnicity. Consanguinity increases the probability of homozygous recessive alleles. No consistent sex bias is expected or established.

10. Diagnostics

Clinical suspicion and criteria

AHS should be suspected in a previously normal or mildly delayed infant/child with new focal—especially occipital—seizures, EPC/status epilepticus, rapid regression, ataxia, visual symptoms, unexplained hepatopathy, or unexpected deterioration after valproate. In the Columbia natural-history protocol, molecularly confirmed AHS required biallelic POLG variants plus epilepsy and either regression or hepatopathy. Without molecular confirmation, refractory seizures, regression, hepatopathy, and supportive imaging/biochemical/pathology findings were required. (NCT03034512 chunk 1)

Testing strategy

Immediately avoid valproate while evaluating a compatible phenotype.
Obtain CBC, glucose, electrolytes, lactate/pyruvate, plasma amino acids, ammonia, AST/ALT, GGT, bilirubin, albumin, INR/PT/PTT, and renal indices. Normal lactate or normal muscle mtDNA does not exclude AHS. (pronicka2011drugresistantepilepsiaand pages 6-7)
EEG: look for occipital/occipitotemporal epileptiform activity, high-voltage polyspike–slow waves, and RHADS. Continuous EEG is appropriate in encephalopathy or suspected nonconvulsive SE. (rahman2019polgrelateddisordersand pages 8-10, hikmat2017theclinicalspectrum pages 4-6)
MRI brain with diffusion and spectroscopy: cortical edema/restricted diffusion and stroke-like lesions, commonly occipital; thalamic lesions, cortical atrophy, reduced N-acetylaspartate, or lactate peaks may support the diagnosis. One pediatric cohort reported lesions in 82% at onset and 88% during follow-up. (hikmat2017theclinicalspectrum pages 4-6)
Molecular confirmation: sequence and deletion/duplication analysis of POLG, preferably on a rapid mitochondrial epilepsy/hepatocerebral panel. Trio WES/WGS is appropriate if panel testing is negative, phenotype is atypical, or an Alpers-like gene is suspected. Confirm phase of two variants through parental testing.
Tissue studies: liver or muscle mtDNA copy number and respiratory-chain assays can support unresolved cases, but depletion is tissue-specific. Biopsy is now secondary to rapid molecular testing and should be performed only if results will change management. Histology may show the characteristic liver lesions described above. (hikmat2017theclinicalspectrum pages 1-2, hikmat2017theclinicalspectrum pages 4-6)

CMA, karyotyping, FISH, repeat-expansion testing, and primary mtDNA sequencing alone have low first-line yield for classic AHS unless another diagnosis is suspected. RNA sequencing may clarify splice variants; untargeted metabolomics/proteomics remain research adjuncts.

Differential diagnosis

Important alternatives include mitochondrial hepatocerebral depletion syndromes due to DGUOK, MPV17, C10orf2/TWNK, FBXL4, mitochondrial aminoacyl-tRNA synthetase disorders (FARS2, NARS2, PARS2), Leigh syndrome, MELAS/MERRF-spectrum disease, pyruvate dehydrogenase deficiency, urea-cycle and organic-acidemia disorders, CDG, Wilson disease in older children, viral/autoimmune encephalitis, FIRES, structural epilepsy, and drug-induced liver injury. The combination of occipital epilepsy/EPC, regression, characteristic liver disease, and biallelic POLG variants is strongly discriminating. (pronicka2011drugresistantepilepsiaand pages 6-7, hikmat2017theclinicalspectrum pages 6-7, rahman2020mitochondrialdiseasein pages 5-6)

There is no population newborn screen. Cascade testing of relatives and targeted carrier testing are appropriate after familial variants are established.

11. Outcome and prognosis

Prognosis in classic childhood AHS is very poor. In the 2017 pediatric cohort, overall mortality was 85% (22/26); median age at death was 15.8 months, median survival from onset 4.9 months, and liver failure caused 13/22 deaths. In the Alpers subgroup, seizures and liver dysfunction each occurred in 100%, with median survival of approximately four months from onset. (hikmat2017theclinicalspectrum pages 6-7)

In the 2024 French cohort of 40 children with biallelic POLG disease, only 6/40 survived; ages at death ranged from 3 months to 10 years. Hepatic presentations began earliest and had the shortest survival. (rotig2024distinctclinicalcourses pages 1-2)

Across the broader 2024 POLG cohort, seizure presence predicted higher mortality; after status-epilepticus onset, median time to death was five months. (hikmat2024statusepilepticusin pages 1-2)

Major complications are refractory SE, acute/chronic liver failure, coagulopathy, hyperammonemia, aspiration, respiratory failure, malnutrition, infections/sepsis, immobility, and profound neurologic disability. Durable neurologic recovery is unusual once regression and recurrent SE are established. No validated molecular prognostic biomarker is available; early hepatic presentation, SE, liver dysfunction, and valproate exposure are adverse clinical indicators.

12. Treatment and real-world implementation

Current strategy

There is no approved curative or disease-modifying therapy. Care should be coordinated by mitochondrial medicine, pediatric neurology/epileptology, hepatology, intensive care, nutrition, rehabilitation, genetics, and palliative-care teams. (rahman2019polgrelateddisordersand pages 11-13, saneto2013alpershuttenlochersyndrome. pages 11-13)

Seizures: levetiracetam, benzodiazepines such as clobazam, lamotrigine, topiramate, or selected sodium-channel agents are used, often in combination. No antiseizure medicine has demonstrated disease-specific superiority. Refractory SE may require ICU anesthetic therapy; ketamine, magnesium, and rarely focal surgery/hemispherectomy have been described in case reports. These interventions control seizures but do not correct POLG deficiency. (rahman2019polgrelateddisordersand pages 11-13, rahman2019polgrelateddisordersand pages 19-20)

Absolute safety point: valproic acid/divalproex is contraindicated in known or suspected POLG disease because it can precipitate fatal liver failure. POLG testing should be considered before valproate in children or adolescents with unexplained epilepsy plus regression, occipital features, or liver abnormalities. (rahman2019polgrelateddisordersand pages 11-13, rotig2024distinctclinicalcourses pages 1-2)

Supportive care: enteral nutrition/gastrostomy, avoidance of fasting, treatment of hypoglycemia/acidosis/hyperammonemia, respiratory support, infection treatment, physical/occupational/speech therapy, management of spasticity/dystonia, visual support, psychosocial care, and early goals-of-care discussions. Folinic acid may be considered only with documented cerebral folate deficiency. Carnitine, coenzyme Q10, riboflavin, thiamine, and antioxidant “mitochondrial cocktails” are used empirically, but controlled evidence of benefit is absent. (saneto2013alpershuttenlochersyndrome. pages 13-14, saneto2013alpershuttenlochersyndrome. pages 11-13, lee2007liverdiseasein pages 9-10)

Liver transplantation: isolated transplantation is generally unsuitable for classic childhood AHS because neurologic disease continues. Historic series show predominantly poor neurologic outcomes; one 2011 series had median post-transplant survival of 2.8 months with no long-term survivors among 17 cases, although selected older POLG patients without advanced neurologic disease have survived for years. Decisions require individualized multidisciplinary assessment and should not generalize adult POLG outcomes to classic AHS. (rahman2019polgrelateddisordersand pages 11-13, rahman2019polgrelateddisordersand pages 29-30)

Suggested NCIt intervention concepts: Anticonvulsant Therapy, Benzodiazepine, Levetiracetam, Lamotrigine, Topiramate, Enteral Nutrition, Gastrostomy, Mechanical Ventilation, Physical Therapy, Occupational Therapy, Speech Therapy, Genetic Counseling, Palliative Care, Liver Transplantation. Exact NCIt codes should be resolved against the current NCIt release.

Trials and emerging therapies

NCT03034512, Alpers Huttenlocher Natural History Study: observational, terminated after enrollment of two participants because of changed research focus. (NCT03034512 chunk 1)
NCT04378075, vatiquinone for mitochondrial disease with refractory epilepsy: phase 2/3, terminated; broader mitochondrial population rather than proven AHS efficacy.
NCT05218655, vatiquinone safety extension: phase 3, completed; not evidence of AHS-specific benefit.

Nicotinamide riboside and metformin have improved mitochondrial or neuronal readouts in patient-derived organoids, but neither has demonstrated clinical efficacy or safety for AHS. Gene replacement/editing, RNA therapy, cell therapy, and mitochondrial transplantation remain conceptual or preclinical for POLG-AHS. (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)

13. Prevention

Because AHS is genetic, lifestyle modification cannot prevent disease in an affected genotype.

Primary prevention: carrier identification in relatives; genetic counseling; IVF with PGT-M for known familial variants; prenatal diagnosis by CVS/amniocentesis; use of donor gametes where desired.
Secondary prevention: rapid diagnosis in at-risk siblings or children with compatible epilepsy; cascade testing; strict avoidance of valproate; early seizure and metabolic-stress management.
Tertiary prevention: avoid fasting and mitochondrially hazardous medicines, maintain nutrition/hydration, promptly treat infection and seizures, monitor liver function/coagulation/ammonia, prevent aspiration and pressure injury, and provide rehabilitation.

No vaccine, public-health environmental intervention, chemoprophylaxis, or population newborn-screening program is applicable. Prenatal and preimplantation testing should target the nuclear POLG variants; mitochondrial replacement therapy is not the standard solution for this autosomal nuclear-gene disorder.

14. Other species and natural disease

No well-established naturally occurring veterinary disease equivalent to human POLG-AHS was identified. POLG orthologs are evolutionarily conserved in mammals and other eukaryotes, preserving mitochondrial DNA replication, but cross-species conservation does not establish a naturally occurring syndrome. There is no infectious transmission or zoonotic potential.

Suggested taxonomy identifiers for experimental work include Homo sapiens NCBI Taxon 9606, Mus musculus 10090, Danio rerio 7955, Drosophila melanogaster 7227, and Saccharomyces cerevisiae 4932. Species-specific POLG/POLG-like gene IDs should be drawn directly from current NCBI Gene/Alliance releases.

15. Model organisms and experimental systems

Traditional POLG mouse models—including mutator, proofreading-deficient, knockout, and tissue-specific models—are valuable for mtDNA mutagenesis, depletion, aging, and bioenergetics but often fail to reproduce the complete human AHS combination of explosive childhood occipital epilepsy, selective neuronal injury, and hepatopathy. This limits their predictive value for therapeutic screening.

The most disease-relevant current models are:

Patient fibroblasts and neural stem cells: demonstrate mtDNA/complex-I loss, ROS excess, altered NAD+ metabolism, senescence, and BNIP3-associated mitophagy.
Patient-derived iPSC neurons: permit analysis of genotype-specific neuronal vulnerability.
Cortical/cerebral organoids: reproduce neuronal loss, astrogliosis, mtDNA depletion and complex-I deficiency and permit transcriptomic and drug-response analysis.
Isogenic CRISPR-corrected or knock-in controls: desirable for separating variant effects from genetic-background effects, although they remain in-vitro systems without whole-body hepatic–neurologic interactions.

The 2024 NR organoid study is the strongest recent AHS-specific model evidence, but it derived from a very small number of patient lines and lacks pharmacokinetics, liver toxicity, immune interactions, and clinical endpoints. (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)

Evidence gaps and expert interpretation

Precise population incidence, prevalence, sex ratio, ancestry-specific risk, penetrance, and carrier frequency for classic AHS remain undefined.
Most treatment evidence consists of retrospective cohorts, case series, or expert practice; no therapy has shown AHS-specific benefit in a randomized trial.
Genotype alone cannot reliably predict the childhood neurologic, hepatic, or gastrointestinal course. (rotig2024distinctclinicalcourses pages 1-2)
AHS-specific quality-of-life instruments, longitudinal biomarkers, single-cell human tissue atlases, and prospective natural-history cohorts are lacking.
The most actionable evidence is preventive: recognize the phenotype early, obtain rapid molecular testing, aggressively manage seizures and metabolic stress, and never administer valproate when POLG disease is known or strongly suspected. (rahman2019polgrelateddisordersand pages 11-13, rotig2024distinctclinicalcourses pages 1-2)

Key recent and authoritative sources

Rötig A, et al. Distinct Clinical Courses and Shortened Lifespans in Childhood-Onset DNA Polymerase Gamma Deficiency. Neurology Genetics. Published August 2024. DOI: https://doi.org/10.1212/NXG.0000000000200167. (rotig2024distinctclinicalcourses pages 1-2)
Hikmat O, et al. Status epilepticus in POLG disease: a large multinational study. Journal of Neurology. Published June 2024;271:5156–5164. DOI: https://doi.org/10.1007/s00415-024-12463-5. (hikmat2024statusepilepticusin pages 1-2)
Hong Y, et al. The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC-Derived Cortical Organoid of Alpers’ Disease. International Journal of Biological Sciences. Published July 2024;20:1194–1217. DOI/preprint record: https://doi.org/10.1101/2023.07.02.547346. (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)
Hayhurst H, et al. Dissecting the neuronal vulnerability underpinning Alpers’ syndrome. Brain Pathology. Published October 2019;29:97–113. DOI: https://doi.org/10.1111/bpa.12640. (hayhurst2019dissectingtheneuronal pages 1-4)
Rahman S, Copeland WC. POLG-related disorders and their neurological manifestations. Nature Reviews Neurology. 2019;15:40–52. DOI: https://doi.org/10.1038/s41582-018-0101-0. (rahman2019polgrelateddisordersand pages 3-4, rahman2019polgrelateddisordersand pages 11-13)
Hikmat O, et al. The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. Genetics in Medicine. Published November 2017;19:1217–1225. DOI: https://doi.org/10.1038/gim.2017.35. (hikmat2017theclinicalspectrum pages 1-2, hikmat2017theclinicalspectrum pages 6-7)

PMID-linked foundational POLG–AHS literature identified through Open Targets: PMID 12707443, 15534189, 17846414, 18828154, 20142534, 22000311, 22237560, 23545419, 25129007, and 27604308; links follow the pattern https://pubmed.ncbi.nlm.nih.gov/12707443/. These records should be individually matched to claims during database curation rather than treated as interchangeable evidence. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)

References

(rahman2019polgrelateddisordersand pages 3-4): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.
(rahman2020mitochondrialdiseasein pages 5-6): S. Rahman. Mitochondrial disease in children. Journal of Internal Medicine, 287:609-633, Apr 2020. URL: https://doi.org/10.1111/joim.13054, doi:10.1111/joim.13054. This article has 235 citations and is from a domain leading peer-reviewed journal.
(hayhurst2019dissectingtheneuronal pages 1-4): Hannah Hayhurst, Maria‐Eleni Anagnostou, Helen J. Bogle, John P. Grady, Robert W. Taylor, Laurence A. Bindoff, Robert McFarland, Doug M. Turnbull, and Nichola Z. Lax. Dissecting the neuronal vulnerability underpinning alpers’ syndrome: a clinical and neuropathological study. Brain Pathology, 29:97-113, Oct 2019. URL: https://doi.org/10.1111/bpa.12640, doi:10.1111/bpa.12640. This article has 31 citations and is from a domain leading peer-reviewed journal.
(rotig2024distinctclinicalcourses pages 1-2): Agnès Rötig, Pauline Gaignard, Giulia Barcia, Zahra Assouline, Claire-Marine Berat, Magalie Barth, Léna Damaj, Nolwenn Laborde, Marie-Thérèse Abi-Warde, Brigitte Chabrol, Pascale De Lonlay, Isabelle Desguerre, Alice Goldenberg, Emmanuel Gonzales, Emmanuel Jacquemin, Patrizia Amati -Bonneau, Dominique Bonneau, Véronique Abadie, Chrystèle Bonnemains, Pierre Broue, Anne De Saint-Martin, Philippe Durand, Alain Fouilhoux, Bertrand Isidor, Marianne Jaroussie, Guillaume Jedraszak, Hélène Maurey, Karine Mention, Sylvie S. Odent, Laurent Pasquier, Christelle Rougeot-Jung, Cyril Gitiaux, Charles-Joris Roux, Nathalie Boddaert, Arnold Munnich, and Manuel Schiff. Distinct clinical courses and shortened lifespans in childhood-onset dna polymerase gamma deficiency. Aug 2024. URL: https://doi.org/10.1212/nxg.0000000000200167, doi:10.1212/nxg.0000000000200167. This article has 12 citations.
(hikmat2024statusepilepticusin pages 1-2): Omar Hikmat, Karin Naess, Martin Engvall, Claus Klingenberg, Magnhild Rasmussen, Eylert Brodtkorb, Elsebet Ostergaard, Irenaeus de Coo, Leticia Pias-Peleteiro, Pirjo Isohanni, Johanna Uusimaa, Kari Majamaa, Mikko Kärppä, Juan Dario Ortigoza-Escobar, Trine Tangeraas, Siren Berland, Emma Harrison, Heather Biggs, Rita Horvath, Niklas Darin, Shamima Rahman, and Laurence A. Bindoff. Status epilepticus in polg disease: a large multinational study. Journal of Neurology, 271:5156-5164, Jun 2024. URL: https://doi.org/10.1007/s00415-024-12463-5, doi:10.1007/s00415-024-12463-5. This article has 21 citations and is from a domain leading peer-reviewed journal.
(hikmat2017theclinicalspectrum pages 6-7): Omar Hikmat, Charalampos Tzoulis, Wui K Chong, Latifa Chentouf, Claus Klingenberg, Carl Fratter, Lucinda J Carr, Prab Prabhakar, Nandhini Kumaraguru, Paul Gissen, J Helen Cross, Thomas S Jacques, Jan-Willem Taanman, Laurence A Bindoff, and Shamima Rahman. The clinical spectrum and natural history of early-onset diseases due to dna polymerase gamma mutations. Genetics in Medicine, 19:1217-1225, Nov 2017. URL: https://doi.org/10.1038/gim.2017.35, doi:10.1038/gim.2017.35. This article has 87 citations and is from a highest quality peer-reviewed journal.
(hikmat2017theclinicalspectrum pages 4-6): Omar Hikmat, Charalampos Tzoulis, Wui K Chong, Latifa Chentouf, Claus Klingenberg, Carl Fratter, Lucinda J Carr, Prab Prabhakar, Nandhini Kumaraguru, Paul Gissen, J Helen Cross, Thomas S Jacques, Jan-Willem Taanman, Laurence A Bindoff, and Shamima Rahman. The clinical spectrum and natural history of early-onset diseases due to dna polymerase gamma mutations. Genetics in Medicine, 19:1217-1225, Nov 2017. URL: https://doi.org/10.1038/gim.2017.35, doi:10.1038/gim.2017.35. This article has 87 citations and is from a highest quality peer-reviewed journal.
(hayhurst2019dissectingtheneuronal pages 13-15): Hannah Hayhurst, Maria‐Eleni Anagnostou, Helen J. Bogle, John P. Grady, Robert W. Taylor, Laurence A. Bindoff, Robert McFarland, Doug M. Turnbull, and Nichola Z. Lax. Dissecting the neuronal vulnerability underpinning alpers’ syndrome: a clinical and neuropathological study. Brain Pathology, 29:97-113, Oct 2019. URL: https://doi.org/10.1111/bpa.12640, doi:10.1111/bpa.12640. This article has 31 citations and is from a domain leading peer-reviewed journal.
(hayhurst2019dissectingtheneuronal pages 10-13): Hannah Hayhurst, Maria‐Eleni Anagnostou, Helen J. Bogle, John P. Grady, Robert W. Taylor, Laurence A. Bindoff, Robert McFarland, Doug M. Turnbull, and Nichola Z. Lax. Dissecting the neuronal vulnerability underpinning alpers’ syndrome: a clinical and neuropathological study. Brain Pathology, 29:97-113, Oct 2019. URL: https://doi.org/10.1111/bpa.12640, doi:10.1111/bpa.12640. This article has 31 citations and is from a domain leading peer-reviewed journal.
(anagnostou2016epilepsydueto pages 11-12): Maria‐Eleni Anagnostou, Yi Shiau Ng, Robert W. Taylor, and Robert McFarland. Epilepsy due to mutations in the mitochondrial polymerase gamma (polg) gene: a clinical and molecular genetic review. Epilepsia, 57:1531-1545, Aug 2016. URL: https://doi.org/10.1111/epi.13508, doi:10.1111/epi.13508. This article has 111 citations and is from a domain leading peer-reviewed journal.
(saneto2013alpershuttenlochersyndrome. pages 1-2): Russell P. Saneto, Bruce H. Cohen, William C. Copeland, and Robert K. Naviaux. Alpers-huttenlocher syndrome. Pediatric neurology, 48 3:167-78, Mar 2013. URL: https://doi.org/10.1016/j.pediatrneurol.2012.09.014, doi:10.1016/j.pediatrneurol.2012.09.014. This article has 158 citations and is from a peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 8-10): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.
(hong2024thenad+precursor pages 10-12): Yu Hong, Zhuoyuan Zhang, Tsering Yangzom, Anbin Chen, Bjørn Christian Lundberg, Evandro Fei Fang, Gareth John Sullivan, Charalampos Tzoulis, Laurence A. Bindoff, and Kristina Xiao Liang. The nad+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in ipsc derived cortical organoid of alpers' disease. International Journal of Biological Sciences, 20:1194-1217, Jul 2024. URL: https://doi.org/10.1101/2023.07.02.547346, doi:10.1101/2023.07.02.547346. This article has 11 citations and is from a peer-reviewed journal.
(hong2024thenad+precursor pages 1-4): Yu Hong, Zhuoyuan Zhang, Tsering Yangzom, Anbin Chen, Bjørn Christian Lundberg, Evandro Fei Fang, Gareth John Sullivan, Charalampos Tzoulis, Laurence A. Bindoff, and Kristina Xiao Liang. The nad+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in ipsc derived cortical organoid of alpers' disease. International Journal of Biological Sciences, 20:1194-1217, Jul 2024. URL: https://doi.org/10.1101/2023.07.02.547346, doi:10.1101/2023.07.02.547346. This article has 11 citations and is from a peer-reviewed journal.
(OpenTargets Search: Alpers-Huttenlocher syndrome-POLG): Open Targets Query (Alpers-Huttenlocher syndrome-POLG, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(NCT03034512 chunk 1): Michio Hirano, MD. Alpers Huttenlocher Natural History Study. Columbia University. 2014. ClinicalTrials.gov Identifier: NCT03034512
(pronicka2011drugresistantepilepsiaand pages 6-7): Ewa Pronicka, Anna Weglewska-Jurkiewicz, Maciej Pronicki, Jolanta Sykut-Cegielska, Pawel Kowalski, Magdalena Pajdowska, Irena Jankowska, Katarzyna Kotulska, Piotr Kalicinski, Joanna Jakobkiewicz-Banecka, and Grzegorz Wegrzyn. Drug-resistant epilepsia and fulminant valproate liver toxicity. alpers-huttenlocher syndrome in two children confirmed post mortem by identification of p.w748s mutation in polg gene. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 17:CR203-CR209, Apr 2011. URL: https://doi.org/10.12659/msm.881716, doi:10.12659/msm.881716. This article has 51 citations.
(hikmat2017theclinicalspectrum pages 1-2): Omar Hikmat, Charalampos Tzoulis, Wui K Chong, Latifa Chentouf, Claus Klingenberg, Carl Fratter, Lucinda J Carr, Prab Prabhakar, Nandhini Kumaraguru, Paul Gissen, J Helen Cross, Thomas S Jacques, Jan-Willem Taanman, Laurence A Bindoff, and Shamima Rahman. The clinical spectrum and natural history of early-onset diseases due to dna polymerase gamma mutations. Genetics in Medicine, 19:1217-1225, Nov 2017. URL: https://doi.org/10.1038/gim.2017.35, doi:10.1038/gim.2017.35. This article has 87 citations and is from a highest quality peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 11-13): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.
(saneto2013alpershuttenlochersyndrome. pages 11-13): Russell P. Saneto, Bruce H. Cohen, William C. Copeland, and Robert K. Naviaux. Alpers-huttenlocher syndrome. Pediatric neurology, 48 3:167-78, Mar 2013. URL: https://doi.org/10.1016/j.pediatrneurol.2012.09.014, doi:10.1016/j.pediatrneurol.2012.09.014. This article has 158 citations and is from a peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 19-20): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.
(saneto2013alpershuttenlochersyndrome. pages 13-14): Russell P. Saneto, Bruce H. Cohen, William C. Copeland, and Robert K. Naviaux. Alpers-huttenlocher syndrome. Pediatric neurology, 48 3:167-78, Mar 2013. URL: https://doi.org/10.1016/j.pediatrneurol.2012.09.014, doi:10.1016/j.pediatrneurol.2012.09.014. This article has 158 citations and is from a peer-reviewed journal.
(lee2007liverdiseasein pages 9-10): Way Lee and Ronald Sokol. Liver disease in mitochondrial disorders. Seminars in liver disease, 27 3:259-73, Aug 2007. URL: https://doi.org/10.1055/s-2007-985071, doi:10.1055/s-2007-985071. This article has 135 citations and is from a peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 29-30): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

Alpers–Huttenlocher Syndrome: Disease-Characteristics Research Report

Executive summary

1. Disease information

Definition and classification

Identifiers and synonyms

2. Etiology and risk/protective factors

Causal factors

Genetic risk and modifiers

Environmental and gene–environment interactions

3. Phenotypes

4. Genetic and molecular information

Causal gene

Variant classes and consequences

5. Environmental, lifestyle, and infectious information

6. Mechanism and pathophysiology

Causal chain

Pathology and biochemical abnormalities

Molecular profiling and advanced technologies

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical suspicion and criteria

Testing strategy

Differential diagnosis

11. Outcome and prognosis

12. Treatment and real-world implementation

Current strategy

Trials and emerging therapies

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Evidence gaps and expert interpretation

Key recent and authoritative sources

Artifacts